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1.1.1 Epidemiology  
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and it is 
responsible for 8 to 10% of pediatric cancers. The incidence is 10.4 / million /for year in 
Caucasians children and 8.3 / million /for year in black children under 15 years [1]. The tumor 
is slightly more common in males (M: F = 1.1:1) [2]. 
The most common site of  event depends on the age of the patient,  it is often in the 
chest  in children under one year (33%), the site i the abdominal region in older infants (55-
75%). The first description of a case of neuroblastoma dates back to 1864 by Virchow, but the 
name was coined by Homer Wright in 1910.  
The average age at diagnosis is 22 months after birth, 97% of cases are diagnosed in 
childhood, only 10% of cases exceeds the age of 5 years old, 1.5% aged over 14 years old [3]. 
The 60% of patients are diagnozed at an advanced stage of disease: this means that in about 









1.1.2 Etiopathogenesis and inheritance  
Although some studies have shown that maternal age (under 20 years) and high blood 
pressure of mother could be considered prenatal risk factors [5], the etiology of NB is still 
poorly understood. Usually NB occurs sporadically, but 5% of patients have a genetic 
predisposition to develop the disease [6]. The famili r NB is inherited in a Mendelian 
autosomal dominant pattern with incomplete penetrance.  
Approximately 22% of NB is caused by a germline mutation [7] and this fits the theory 
proposed by Knudson for the origin of pediatric tumors [8], where two mutations in a post-
zygotic single cell define a non-hereditary NB. Hereditary NB show instead a germline 
mutation which is followed to a somatic mutation. Other studies confirm this ipothesis 
underlined the role of ALK and PHOX2B genes in the progression of hereditary NB [9] [10].  
Neuroblastoma arises from neuroepithelial primitive cells of the neural crest and it is 
localized mainly in the adrenal gland (50%), in retroperitoneal region (25%), in chest area 
(15%), in pelvis  and in pre and para-vertebral sympathetic ganglia (5%). 
These tumors show a spontaneous or induced differentiatio  in ganglioneuroblastoma but the 
differentiating factors are not known. An important system seems to be the homologous 
family of neurotrophins (NGF, BDNF, NT3, NT4/5) and their receptors (TrkA, TrkB and 
TrkC): activation of TrkA leads to inhibition of growth, inhibition of angiogenesis, increased 
chemotherapeutic sensitivity and induction to differentiation. In contrast, activation of TrkB 
promotes the proliferation, invasiveness and chemotherapeutic resistance [11].  
Chromogranin A and neuropeptide Y are two other markers of neuronal differentiation 
and sometimes they are associated to NB differentiation.  
Chromogranin A is an acidic protein,  and it is a component of granules of neurosecretion of 
cells, of tissues and of neuroendocrine tumors, andits expression is regulated during 
development [12] [13] [14]. This protein is present in NB patients' serum and it can be useful 
as a sensitive and specific marker of the disease activity and of the response to treatment [15] 
[16].  
Neuropeptide Y is a neurosecretory protein whose expression is regulated in the development 
and related to the nervous system [17] [18]. These two proteins may be useful to characterize 









The vasoactive intestinal peptide (VIP) and somatost in  are other peptide hormones 
associated with the neuroblastoma. The expression of somatostatin receptors in NB cell is 
correlated with higher histological differentiation, a more low-stage disease and a favorable 
outcome [22] [23] [24]. The expression of VIP is associated with differentiated tumors, and it 
can induce in vitro neuronal differentiation in NB cells [25] [26]. The role of these two 
proteins in regulating growth and differentiation of sympathetic neurons during normal 
development is not yet clear.  
 
1.1.3 Histopathology  
The histopathological classification highlights four classic histologic types that have 
varying degrees of maturation and differentiation [2]:  
•  neuroblastoma is the most malignant histological type, it is characterized by small, 
uniform cells called 'small round blue cells'. These cells present dense and hyperchromatic 
nuclei and scant cytoplasm. The presence of neuritic processes, or neuropil, is a characteristic 
feature especially of primitive NB. 15-50% of cases present the Homer-Wright pseudorosette, 
it is a ring of  neuroblasts surrounding areas of  e sinophilc neuropil;  
•  ganglioneuroma is the benign and fully differentiated counterpart of neuroblastoma. It 
is composed primarily of mature ganglion cells, neuropil and Schwann cells;  
•  ganglioneuroblastoma defines a heterogeneous group of tumors with  histopathologic 
features spanning the extremes from a predominance of neuroblastic elements with rare 
maturing cells to neoplasms comprised almost exclusively of ganglioneuroma and containing 
occasional rest of neuroblasts; 
•  nodular ganglioneuroblastoma is composed by rich or poor in stroma cells and by 
neuroblasts to variable differentiation.  
 
1.1.4 Staging  
Different staging systems were developed in the last forty years: the clinical-
instrumental classical method, proposed by Evans in 1971 [27], the system used by St. Jude 









classification [30] [31]: they allow to distinguish between low-stage patients with good 
prognosis and those patients at high stage with poor r gnosis. Especially for patients at 
intermediate stages, there are substantial differenc s between the various staging systems. For 
this reason  the International Neuroblastoma Staging System (INSS) has been created which 
incorporates the main points of Evans, the POG, in light of the different criteria for assessing 
the therapeutic response [32] [33] [34].  
                        International Neuroblastoma St ging System Stages 
Stage 1:   localized tumor with complete gross excision, with or without microscopic residual  
disease; representative ipsilateral lymph nodes negative for tumor microscopically  
(nodes attached to and removed with the primary tumor ay be positive).  
Stage 2A:  localized tumor with incomplete gross excision; representative ipsilateral     
                   nonadherent lymph nodes negative for tumor microscopically.  
Stage2B: localized tumor with or without complete gross excision, with ipsilateral 
nonadherent lymph nodes positive for tumor. Enlarged  
contralateral lymph nodes must be negative microscopically.  
Stage 3:  unresectable unilateral tumor infiltrating across the midline, with or without 
regional lymph node involvement; or localized unilater l tumor  
with contralateral regional lymph node involvement; or midline tumor with  
bilateral extension by infiltration (unresectable) or by lymph node  
involvement. The midline is defined as the vertebral column. Tumors  
originating on one side and crossing the midline must infiltrate to or  
beyond the opposite side of the vertebral column.  
Stage 4:   any primary tumor with dissemination to distant lymph nodes, bone, bone  
marrow, liver, skin, and/or other organs (except as defined for  
stage 4S).  
Stage 4S:   localized primary tumor (as defined for stage 1, 2A or 2B), with dissemination 
limited to skin, liver, and/or bone marrow (limited to  
infants less than 1 year of age). Marrow involvement should be minimal  
(i.e., <10% of total nucleated cells identified as malignant by bone  
biopsy or by bone marrow aspirate). More extensive bone marrow involvement  









iodobenzylguandine (MIBG) scan (if performed) should be negative for  
disease in the bone marrow.  
 
1.1.5 Genetics of neuroblastoma  
The identification and staging of neuroblastoma are not based only on clinical and 
structural prediction models, like INSS; in fact the alterations at the genomic level play a 
crucial role in the prognosis of this malignancy.   
         All the neuroblast tumors can therefore be divided into two main subgroups based on 









             
 
 
Fig.1  Genetic characteristics and biological pathway in neuroblast tumors. Neuroblastoma tumors can be 
subdivided into two biological/clinical groups: 'benignly' behaving neuroblastomas are indicated by a green 
background, aggressive neuroblastomas are marked by a orange or red background.  
The 'beningly' behaving neuroblastomas virtually always show a near-triploid, near-pentaploid or near-hexaploid 
DNA Index, without any structural aberrations: in a) nuclei with a typical I-FISH picture with 3 spots each for 
D1Z2 at 1p36 and D1Z1 for the para centromeric region of chromosome 1 shown. Spontaneously maturing 
tumours show two types of cells, but only a small fraction of the cells are tumour cells. In b) one anuploid 
ganglionic cell with reddish cytoplasm is shown besid  a majority of cells showing 2 signals with all used FISH 
probes representing non neoplastic Schwann cells. Neuroblastomas with aggressive clinical behavior can further 
be subdivided in those without MYCN amplification but with segmental aberrations like del1p, del11q, add17q 
(shown in c): tumor cells with only 1 sub-telomeric I-FISH signal in red and 2 paracentromeric I-FISH spots in 
green) and those with MYCN amplification (an example is given in d): tumour cells displaying both types of 










The importance of the cellular content of DNA is demonstrated by flow cytometry in children. 
In fact, children with tumors that have a hyperdiploid content of DNA (DNA index > 1) have 
generally low stages of the disease and they respond to initial therapy, while NB tumors with 
a diploid DNA content (DI = 1) usually have advanced stages of disease and do not respond 
to certain combinations of chemotherapy [35] [36].  
Near triploid (-penta, hexaploid) neuroblastomas (±3N) represent about 45% of 
neuroblastomas, with a survival of approximately 100% and they can be compared to stages 
1, 2, 4S of the INSS. Genetic alterations include a gain of genetic material on chromosomes 2, 
7, 9, 12, 17 and a loss for chromosomes 3, 4, 6, 11, 14 [37] [38] [39]. In particular, specific 
gains in chromosome 7 (7p11.2p22) are associated with a higher probability of survival in 
patients with neuroblastoma in recovery [39].  
The tumor may undertake a spontaneous maturation in 22% of cases. This subset of 
patients, however, shows a distinct diploid genotype, due to a large number of non-cancerous 
cells, mainly Schwann cells, involved in maturation. The component with triploid DNA 
borders 1% and it is mostly made up of ganglion cells.  
Di-tetraploid neuroblastoma (2N/4N) constitute the remaining 55% of cases, they are 
identified by a poor prognosis and are characterized by specific genetic alterations (deletions, 
translocations) (INSS Stage 4). 
22% of these tumors show amplification of the MYCN gene, alterations at the genomic level, 
association with advanced disease, rapid tumor progression and poor prognosis [40] [41]. The 
amplification of MYCN in human neuroblastoma was dicovered for the first time by Schwab 
in 1983 [43]. Following studies have confirmed that amplification of the MYCN gene greater 
than 10 copies for haploid genome, it's an unfavorable prognostic indicator, independent of 
the anatomical state, age, and other biological parameters.  
In the cytogenetic analysis the manifestation of the MYCN gene amplification are the 
extra chromosomal chromatin bodies, called double-minutes chromatin bodies (DMs) and the 
chromosomal regions that do not undergo banding, called homogenously staining regions 
(HRSs) [42]. The genetic material from chromosome region 2p24 is in fact transported 
through the DMs during the amplification process and these are then integrated into a random 









lines [40]. The HSRs are generally located on different chromosomes, not in the resident site 
2p24 of MY CN [43] [44]. The values of amplification in neuroblastoma can change between 
5 and more than 500 copies, but usually the number of copies seen in cancers values are 
approximately 50-100 copies.  
The deletion of the short arm of chromosome 1 (1p,36) seems to play a key role in the 
progression of these tumors and prognosis [45]: it is in fact the common alteration presents in 
the most aggressive NB. The 1p region can contain one r more tumor repressor genes 
important in neoplastic transformation or progression of neuroblastoma [46]. The deletion at 
1p is associated with MYCN amplified neuroblastomas and poor prognosis, however, rare 
cases of MYCN not amplified neuroblastoma show a deletion of a smaller number of bases  in 
chromosome 1p and a similar outcome [37]. 
Another important aberration is the gain in chromosome 17. The 17q gain is more 
common in children over one year of age, with tumors at an advanced stage, showing the 
absence of 1p, MYCN amplification and diploid - tetraploid DNA content. The gain in 
position 17q is the result of a translocation betwen chromosomes 17 and 1. 
The remaining 38% of tumors presents deletions in chromosomes 1, 3, 4, 11, 14, as well 
as gains on chromosome 17 [37] [39] and no MYCN amplification. Experimental studies have 
demonstrated that the gain on the q arm of chromosoe 17 is significantly associated with 
tumor progression [25] even among patients without MYCN amplification or 1p deletion [47] 
[48]. Each translocation of material in 17q is associated with events of deletion in "partner" 
chromosomes (1p, 11q). In this case, this subclass of diploid neuroblast tumors shows a 
translocation between chromosome 17 and 11.  
 Rearrangements of 11q were observed in many patients, which is a deletion of 11q23-
qter, balanced translocations involving 11q21 and 11q22, and an inversion of 11q21-q23 [49]. 
The role of these alterations is not clear, but it has been assumed that the rupture of one or 
more genes on 11q may predispose to the development of neuroblastoma. Small deletions of 
11q usually occur in no MYCN amplified neuroblastomas [37] [50]. The loss of 11q is 
significantly associated with adverse clinical parameters, such as older than 1 year, 4-stage 
disease and unfavorable histology [51].  









described above are essential in identifying the different stages of neuroblastoma, but other 
genetic alterations included in the same chromosome regions possess th ame predictive 
power against the disease. 
The high proportion of translocations in 17q and the combination with a low survival 
rate, leading to think that in the additional region of 17q are found genes important for tumor 
progression. The survivin gene is one of the possible candidates: the survivin is an anti 
apoptotic protein that maps in the 17q25; it's exprssed in many cancers (stomach, lung, 
pancreas) and its expression is indicative of a high degree of malignancy, poor prognosis and 
probability of relapse [52] [53].  
Array CGH studies have also highlighted a possible ro of retinoic acid receptor α
(17q21), the receptor for nerve growth factor NGF (17q21.22) and NM23 gene (17q21.3) as 
possible tumor markers: in particular the last of these is over expressed and amplified in 
MYCN amplified neuroblastomas [54].  
Another gene noteworthy is CAMTA1 (Calmodulin-bindig trascriptors Activators). 
This cistron unit belongs to the family of calmodulin-binding transcription factors and it lies 
in the short arm of chromosome 1 that it is deleted in neuroblastoma stage IV and this gene is 
poorly expressed in MYCN amplified neuroblastomas. Moreover the low levels of expression 
of CAMTA1 define a poor prognosis even in the absence of 1p deletions  [55].       
   
1.1.6 Genetic model of neuroblastoma development 
The genetics and genomics research suggest there ar at least two subsets of 
neuroblastomas that are highly correlated with clinical behavior. One classification takes into 
account the assessment of DNA content; MYCN copy number; abnormalities of 1p, 3p, 11q, 
and other changes; the expression of TrkA or TrkB. Genomic data analysis of the different 
mutations have allowed to construct an evolutionary model that explains how, starting from a 



















Fig.2 Genetic model of neuroblastoma development. 2N = diploid karyotype; 3N = triploid karyotype; 2N/4N = 
di-tetraploid karyotype. 
 
It is possible that all neuroblastomas have a common ancestor diploid cell, but a 
commitment is made fairly early to develop into one f two major subtypes:  
Type 1. This subtype is characterized by mitotic dysfuction leading to a hyperdiploid or 
near-triploid modal karyotype with low chromosome rearrangements, no amplification of 
MYCN, deletions in 1p and gain in 17q, high expression of TrkA receptor. These tumors are 
prone to differentiation or undergo programmed cell d ath, depending on the presence or 
absence of NGF in the microenvironment. These genetic r presentation belong to patients 
with 1, 2 and 4S stages of the disease. 
Type 2. It represents the most aggressive neuroblastomas with di-tetraploid karyotype 
with high expression of the receptor TrkB. Within this type, two subsets can be distinguished: 
Type 2A is characterized by alterations in 3, 11 and 17 chromosomes; lack of MYCN 
amplification and 1p deletion.  Representative patients show 3 and 4 stages of the disease and 
they are older.  
Type 2B is characterized by alterations in 1 and 17 chromosomes and amplification of 
MYCN. Representative patients belong to 3 and 4 stage  of disease and they are usually 










This model is similar to that proposed by Sven Bilke and co-workers, as the result of an 
analysis conducted on different patients at different stages of the disease (1, 4, 4S) [56]. 
The model proposed by Bilke shows that more aggressiv  stages of the disease (with or 
without MYCN amplification) have evolved separately and have developed different 
mutations than less aggressive stages (1, 4S). Such genetic diversity reflects perfectly those at 
the clinical level; according to the INSS in fact the patients with 4 stage, with or without 
MYCN amplification, are the major causes of a poor prognosis [56]. 
 
        1.1.7 Diagnosis and treatment 
Neuroblastomas generally arise in the adrenal medulla or along the sympathetic chain. 
To confirm this diagnosis, it is required an histological evidence on primary tumor biopsy to 
confirm the neural origin, accompanied by measure of increase level in urinary catecholamine 
metabolites. Because the bone marrow is frequently involved, children older than 2 years with 
metastatic disease may not require a biopsy but NB can be diagnosed  based on the presence 
of neuroblastic cells involving the bone marrow. On bioptic or bone marrow materials 
MYCN, ploidy and histology studies are evaluated, because tumor specific genetic markers 
and histo pathological evaluation are critical determinants of treatment planning [2]. For 
tumor staging, meta-iodobenzylguanidine (MIBG) scintigraphy (or a technetium-99 bone scan 
in case of negative MIBG), computed tomography or nuclear magnetic resonance, and 
bilateral bone marrow aspirates and trephine biopsies are valuable methods.  
According to risk group assignment, there are the following treatment modalities: 
surgery, standard chemotherapy, intensive multiagent chemotherapy, myeloablative 
chemotherapy, followed by autologous stem cell transplantation, external radiation therapy, 
13-cis retinoic acid, anti-GD2 monoclonal antibody adjuvant therapy, MIBG-therapy . 
For patients with low risk NB that belong to stage 1, 2 and 4s, chemotherapy and 
radiation are usually avoid; for patient with intermediate-risk NB  that belong to stage 3, 
chemotherapy and radiation are used cautiously and individualized as needed; for patient with  
high risk NB that belong to stage 4 metastatic NB diagnosed after 18 months of age or that 
presents MYCN amplification, a multimodal approach is needed.  These treatments are 









Chemotherapy is certainly the predominant modes of treatment NB 
patients and metastatic forms of localized un-resectable neuroblastoma at diagnosis. The 
chemotherapy is also used in patients at lower riskwith important symptoms. Several 
international groups have developed a model of stratification. 
Among the various protocols used, the European protocol currently used for high-risk 
neuroblastoma see a rapid treatment that give cisplat n [C], vincristine [O], carboplatin [J], 














Fig. 3: Treatment schedule of Neuroblastoma-1 high-risk according to the Society of Paediatric European 
Oncology Group Neuroblastoma (HR-NBL1/SIOPEN). COJEC schedule include different drugs and different 
way to administer the drugs: carboplatin CBDCA 750 mg/m2, rapid infusion; etoposide VP-16 175 mg/m2, 
infusion for 4 hours; vincristine VCR 1.5 mg/m2 IV bolus; cisplatin CDDP 80 mg/m2 24 hours of continuous 
perfusion; cyclophosphamide CY 1.050  mg/m2 rapid infusion. Each arrow indicates a single dose f medication 
according to the amount set out in schedules A, B, C.  
 
The goals of primary surgery are to establish the diagnosis, to provide tissue for 
biologic studies, to stage the tumor surgically, to attempt to excise the tumor without injury to 
vital structures, and during second look surgery the goals are to determine response to therapy 
and to remove residual disease.  
The radiation therapy has been used for local control of primary tumor and refractory 









secondary to hepato megaly and when the treatment is i effective. 
Stem cell transplantation is used to destroy the patient's neuroblastoma-infected bone 
marrow and replace it with stem cells that are relatively free of neuroblastoma. 
Immunotherapy is used  after tumors have been surgically removed, when the patient 
has only minimal disease left. This treatment is deigned to train the body's own immune 
system to detect and destroy neuroblastoma cells that have survived chemotherapy or 
radiation therapy.  
 
1.2 MYCN Gene 
1.2.1 MYC gene family 
       The family of proto-oncogenes MYC is composed of a group of transcription factors 
belonging to the class basic-helix-loop-helix-zipper (bHLHZ). The Myc proteins family is 
involved in the regulation of proliferation and cell cycle [58], in the processes that lead to 
differentiation and to apoptosis, in genomic instability and neoplastic transformation [59]. 
MYC genes are among those most frequently involved in human cancers [60]. 
Most studies on gene MYC is focused on three members (c-MYC, MYCN and L-MYC), 
which, when activated, appear to be important in the development of various human cancers 
[61]. c-MYC was the first of the three to be discovered through its homology with v-MYC, 
the transforming gene of the MC29 virus of avian myelocytic [62]. MYCN and L-MYC were 
subsequently identified through their homology with v-MYC amplicons in the cells, 
respectively, of neuroblastoma [63] and small cell lung cancer [64]. To this family it belongs 
to at least three other genes: S-MYC, B-MYC and P-MYC. The proteins encoded by the first 
two appear to suppress the neoplastic transformation s opposed to c-MYC, MYCN and L-
MYC [65] [66] [67]. P-MYC is instead a pseudogene derived from a region of L-MYC [68]. 
The MYC genes can be activated through different mechanisms such as gene amplification 
[69], the chromosomal translocation [70], proviral nsertion [71], retroviral transduction  [72] 
and other processes not yet known. The members of this amily play a key role in activating 
and control of gene expression: in fact they have the same structural motifs present in many 
transcriptional factors. Such as those present in the oncoproteins v-Fos and v-Jun, leucine-
zipper motifs are set in the C-terminus of the protein where, due to their α-helices, they are 









already identified in several transcription factors, such as proteins E12 and E47 [75]. Myc 
proteins also contain a stretch of basic amino acids upstream of helix-loop-helix motif. This 
pattern, called "basic region”, was previously identified in the myogenic transcription factor 
MyoD, which is the region involved in sequence-specific DNA binding [76]. Considering all 
these structures Myc gene family contain a motif of bZIP-bHLH able to interact with DNA in 
which the bZIP and bHLH domains lie in adjacent positi ns separated by only a basic 
domain "b ". Unlike normal bHLH domains, it allows fusion of that structure to hang the 
DNA through the basic regions of bHLH motif, while any dimerization (Myc-Max) of 









Fig. 4 Structure of a bZIP-bHLH motif: we can see Myc-Max heterodimer and the binding with DNA.  
 
1.2.2 From MYCN gene to N-myc protein  
The MYCN oncogene was identified in 1983 due to its partial homology with the proto-
oncogene c-MYC in neuroblastoma cell lines with DMs (double minute chromatin bodies) 
and / or HSRs (homogeneously staining regions) [63] [78]. In situ hybridization allowed us to  
locate on the short arm of human MYCN distal chromosome 2, region 2p23 -24 [79]. Only 
the second  and third exons of the gene are translated and they lead to the formation of the 
protein.  
The post-transcriptional regulation of MYCN is influenced by a signal of ribosomal 
internalization located at 5'-UTR of the mRNA of the gene, which amplifies the translation 









neuroblastoma is ATP dependent and it is mediated by the 26S proteasome in the nucleus; 
degradation can however be done by the employee via calp in [81]. 
MYCN acts as a classic dominant oncogene. The forced expression of MYCN can 
transform normal cells, usually it happen in cooperation with the RAS oncogene [82] [83] 
[84]. The over-expression of MYCN can release the embryonic fibroblasts from the 
senescence [85], the addition of a RNA antisense MYCN in cell lines of neuroblastoma that 
over-express MYCN can reduce the proliferation or induce differentiation and / or its 
apoptosis [86] [87]. In addition, the over-expression of human MYCN in the neuroectoderm  
of the transgenic TH-MYCN mouse produces, in a dose-dependent way, neuroblastoma 
tumors resembling  [88].  
        N-myc protein is a nuclear phosphoprotein wth a short half-life (30-50 min) [89] and it 
shows regions of high homology (overall 38% amino acid identity) with c-myc [90]. Like all 
the MYC family proteins, N-myc has three specific amino acid sequences [91]: 
• a globular domain of transactivation in N-terminus, containing the Myc Boxes I (MBI) and 
II (MBII): they contain regions rich in glutamine and proline, and an acid region essential for 
all known biological activities of N-myc protein. The transactivator domain is involved in the 
balance between apoptotic and proliferative signals [92] and it is also the binding site of 
proteins that regulate the activity of N-myc;  
• an unstructured intermediate region  
• a C-terminus domain containing a basic region (BR), which is involved in the recognition 
and specific binding to DNA [93], a pattern helix-loop-helix/leucine zipper (bHLH-LZ), 














Fig. 5 Structure of N-Myc protein. We can see an N-terminus with Myc Boxes I (MBI) and II (MBII), an acid 
region, a NLS, a C-terminus domain containing a basic region (BR), a pattern helix-loop-helix/leucine zipper 
H1-L-H2-Zip. 
 
Some studies showed that the protein Myc may form co plexes with DNA only at very 
high concentrations, indicating that these interactions may not be physiologically significant 
[94]. So it was supposed that Myc required interaction with a second protein to play its role as 
a transcription factor. It's subsequently identified a small protein called Max [95].  
Max is a ubiquitous nuclear protein with a long half-life, similar to Myc because it also 
contains helix-loop-helix and leucine-zipper basic motif, and it was therefore considered a 
possible dimerization partners. By in vitro assays we have seen that Max is able to form 
dimeric complexes with each members of Myc family, at a concentration lower than the 
concentration required for homodimerization of Myc.  
During G0 phase of cell cycle, the expression of Max is high and it favors the formation 
of homodimers Max/Max, this complex are able to repress transcription. Heterodimerization 
of N-myc and Max usually corresponds to an increased production of N-myc. This complex 
binds DNA specifically to a palindromic nucleotide s quence CACGTG, called E-box [96]; 
another binding site between N-myc and DNA is constituted by asymmetric sequence 









by transcription factors such USF, TFE3 and TFEB. This leads to an great series of 
transcriptional activation of genes that promote cell growth [97]. 
Myc is also able to suppress the activity of other specific genes, although the molecular 
mechanisms underlying these processes are not yet known. 
The repression mechanism does not appear to involve direct interaction with DNA; 
Myc, in fact, raised to the level of promoters through protein-protein interactions with 
positive transcription factors, such as TFII-I, NF-Y and Miz-1, or actively recruiting co-
repressive protein [98].  
Despite the structural and functional homology, the expression of c-MYC and N-myc 
are very different [99]: c-myc is ubiquitous express d in proliferating cells, while N-myc has 
a pattern of expression quite restricted [100]. Thedevelopment of mouse shows that N-myc is 
mainly expressed during the early stages of differentiation: at the birth it still express in brain, 
kidney, intestines, heart and lungs, but it is subsequently down-regulated and in the adult 
mouse its expression occurs mainly in the early development of B lymphocytes [100].  
In 1997 Wakamatsu and co-workers [101] found that, during the development of the 
neural crest of chicken embryos, N-myc is initially expressed in the entire cell population. 
This expression is turned off during the colonization of the ganglia and of the spinal cord, 
except for cells to undergo neuronal differentiation. The high expression of N-myc results in a 
massive migration of the population of ventral neural crest and subsequently these cells 
migrate into the ganglia subjected to neuronal differentiation. Then N-myc is involved in 
regulating the fate of neural crest in two aspects: the ventral migration and neuronal 
differentiation.  
The transcript of N-myc is rather complex: it begins i  different sites that can be 
grouped under the control of two promoters; the multiplicity of sites to start combines with 
alternative splicing to generate two forms of mRNA. The mRNAs have different 5' leader 
sequences but identical structure. Both forms of mRNA are unstable with a half-life of 15 
min. They encode the two N-myc proteins of 65 and 67 kD [102]. However, the first 
alternative exons contain open reading frames distinct, which can diversify the coding 
potential of the gene, and this reflects the complexity of the control of gene expression. Both 









nucleus linked to single-or double-stranded DNA [89].  
 
1.2.3 Role of MYCN in neuroblastoma    
Approximately 25-30% of primary untreated NB shows the amplification of MYCN, 
which is associated with advanced disease, rapid progression and poor prognosis [91]. The 
reason of this association is still uncertain. There is also a direct correlation between the levels 
of N-myc protein and the aggressiveness of this tumor [104]. 
MYCN amplification in human neuroblastoma was discovered in 1983 by Schwab and 
colleagues [63]. Following studies have confirmed that the presence of more than 10 copies of 
MYCN gene per haploid genome is an unfavorable prognostic marker, independent from 
other parameters. 
The MYCN amplification was identified as a single gnetic factor which adds a 
prognostic significant information to clinical varibles such as age and stage [105], in fact, 
currently the status of MYCN is the only genetic variable of cancer used as a criterion for 
stratification of treatment in clinical trials of NB.  
In 1997 Weiss W.A. and his group showed that MYCN contributes to the genesis of 
neuroblastoma with the creation of a transgenic mice that over-express MYCN in neuro-
ectodermal cells and for this develop neuroblastoma [88].  
Amplified copies of MYCN gene can be present either as extra chromosomal DMs, that 
as intra chromosomal HSRs. The DMs predominate in primary tumors and the HSRs are 
present in cell lines [79]. The HSRs are generally located on different chromosomes, not in 
the  2p24 MYCN site [79] [106]. The values of amplification in neuroblastoma can vary 
between 5 and more than 500 copies, but usually in tumors there are values around 50-100 
copies. MYCN can be duplicated in the 2p24 site, as shown  in FISH data [107]. It is not clear 
whether the duplication represents a prelude to amplification or an alternative pathway for the 
activation of the oncogenic potential of MYCN. The number of copies of MYCN is usually 
present in a tumor in different moment during the development and this suggests that 
amplification of MYCN in positive tumors is usually present at diagnosis [103].  
Usually there is a positive correlation between the number of copies of  MYCN gene 









exist [109]. For in vitro analysis, there are few cell lines that express high levels of mRNA or 
N-myc protein, without gene amplification [41] and this is due to alterations in the pathway of 
protein degradation or loss of self-regulation of gene transcription [40] [41]. 
The molecular mechanism of MYCN amplification remains enigmatic. According to 
one of the most accredited models, the amplification mechanism involves a extraordinary 
replication of DNA, a recombination and the formation of a extra-chromosomal circular DNA 
(DM), followed by the integration into a chromosome and subsequent amplification in situ 
(HSR) [110].   
MYCN is centrally located in the DNA amplified and its coding region has never been 
affected by recombination. The length of amplified DNA comprising MYCN can range from 
100 kb to more than 1 Mb [110]. These large dimensions raised the possibility that other 
genes are co-amplified. Various studies found that e single gene consistently amplified is 
MYCN, although in approximately 50-70% of cases of NB positive to MYCN, DDX1 gene  
is co-amplified [111] [112]. It has also been shown that neuroblastoma amplified genes 
(NAG) are co-amplified in 70% of NB with MYCN amplified [113] but never we have seen   
amplification of DDX1 or NAG without the amplification of MYCN. This suggests that 
MYCN is functionally responsible for the maintenance of DNA amplification in 2p24.  
The amplification of MYCN is associated with the development of several pediatric 
tumors, as well as NB: glioblastoma (< 5%), medulloblastoma (5-15%), melanoma of 
neuroectoderm tumor, astrocytoma, small cell lung cancer (10%) and retinoblastoma (10-
20%).  
 
1.2.4 p53 and MYCN in neuroblastoma    
p53 is a nuclear phosphoprotein, that function as atranscription factor. The human gene 
is located on chromosome 17 and mouse gene on chromosome 11, it encodes a tetrameric 
polypeptide of 393 amino acids. p53 is composed of several functional domains [114]: 
• an amino-terminal region whose function is to interact with various components of the 
transcription complex; 









• a central domain, responsible for binding to specific DNA sequence; 
• a c-teminal region that regulates its oligomerization and localization inside the cell and that 
contains several sites of non-specific DNA binding  
p53 binds a consensus sequences on the DNA and it activates or represses the transcription of 
several genes (Fig. 6). 
 
Fig. 6 Some genes involved in p53 pathway. 
 
 Depending on what type of genes p53 activates, that it c n stimulate apoptosis or inhibit cell 
cycle progression or promote DNA repair or induce differentiation [115] [116]. Normally p53  
intracellular levels are low because the protein is rapidly degraded by ubiquitin-dependent 
proteolysis induced by Mdm2 factor. Following stress signals p53 can be activated with a 
consequent increase of intracellular levels. This increase is mainly due to an increase of the 
stability of the protein, but we can not exclude the presence of  a transcriptional or 
translational control. The stress signals that activ te p53 are represented by DNA damage, 









growth factors [114] [115] [116]. 
       Mutations in p53 or alterations in the p53 pathway are frequent in human tumors 
[116]. p53 is involved in both hereditary and sporadic tumors. Li-Fraumeni syndrome is a rare 
hereditary disease transmitted as an autosomal dominant character. In this ereditary tumor p53 
mutation is present in the germ line. Individuals with this disease develop various types of 
primary tumor in different organs and tissues in young age. In rare cases the Li-Fraumeni 
syndrome with p53 germline mutation developed neuroblastoma [117] [118]. Mutations in 
p53 are found in 50% of sporadic human cancers [119]. These mutations 
affect mainly exons 5, 6, 7, 8  [119] [120]. 
   Neuroblastoma at diagnosis presents a low frequency of p53 mutation (< 2%) [121]. It 
appears that p53 can present mutations more commonly in cell lines 
derived from relapsed patients. In some indifferentiated neuroblastoma, the sequestration of 
p53 in the cytoplasm alters the normal G1 checkpoint after DNA damage 
[122] [123]. Although many studies have shown that in some neuroblastomas p53 is 
sequestered in the cytoplasm, recently it is shown that cytoplasmic localization and iper 
ubiquitination of p53 is the result of reduced interaction of p53 with HAUSP [124]. 
Many studies have demonstrated an important role of p53 in chemotherapy response in 
neuroblastoma. In vitro studies using p53 wild type NB cell lines and p53 mutated NB cell 
lines show that the cell lines with p53 inactivated are less responsive to chemotherapic drugs  
[125][126]. In vivo studies using a MYCN transgenic mouse model and a transgenic p53 
aploinsufficient mouse model show that the p53 mouse model is more resistant to treatment 
with cyclophosphamide and show in this model reduce levels of apoptosis and PUMA, BIM, 
and BAX genes [127].  
 
       1.3 Peptide Nucleic Acid  
        1.3.1 Structure and properties  
The PNAs are synthetic analogs of nucleic acids, in which the normal phosphodiester 
backbone is replaced by a pseudo-peptide chain composed of monomers of N-(2-aminoethyl) 
glycine. The nucleobases are covalently linked to this structure through a polyamide-carbonyl 









Despite these changes with respect to natural nucleic acids, the PNA bind sequence-
specific DNA and RNA according to the rules of Watson-Crick pairing [129]. The PNA can 
hybridize with complementary sequences of DNA or RNA, according to two schemes:   
• PNA containing the four natural nucleobases, hybridize with complementary nucleic 
acids according to the rules of base pairing Watson-Crick. Result of the pairing is a duplex 
PNA / DNA or PNA / RNA that resembles the shape of B DNA [130] [132]; 
• PNA containing only pyrimidines (T or C) can hybridize with complementary 
sequences of DNA double strand. In this case, the PNA invades the double helix of DNA and 
hybridizes with the target sequence, while the second strand of DNA is removed and forms a 
“D” loop [128]. So a triplex is formed PNA / DNA / PNA, in which a portion of the PNA 
binds to the target sequence according to the rules of standard Watson-Crick pairing, while 
the other portion of the PNA forms the third strand of the triplex with a Hoogstein pairing 
[129] [132].  
The PNA are achiral and non-ionic molecules, and the lack of electrostatic repulsion 
between the filaments makes the hybrid duplex PNA / DNA and PNA / RNA more stable than 
the natural homo-and hetero-duplex [133]; they are not substrates of hydrolytic enzymes as 
proteases and nucleases, so they are not degraded in cells and are extremely stable in 
biological fluids [133]. 
Since the PNA and DNA have no functional groups in common with the exception of 
nitrogen bases, their chemical properties differ significantly from those of DNA.  
The compounds are neutral and therefore have a low solubility in water compared to DNA. 
The neutral PNA molecules have a tendency to form aggregates in the nucleotide sequence-
dependent manner. The solubility of PNA is also linked to the length of the oligomer and the 
purine relationship: pyrimidine [134]. Some modifications, including the incorporation of 
positively charged lysine residues, showed an improvement in solubility. To increase the 
solubility in water, can also be introduced negative charges, especially in the PNA-DNA 
chimeras. 
 The extinction coefficients of the PNA monomers are not well characterized as those of 
DNA and RNA. It is expected that the PNA oligomers have extinction coefficients different 









the π system of nucleobases. For this reason, for all prctical purposes the concentration of a 
PNA oligomer is determined by measuring the absorbance at 260 nm at 80°C [135]. At this 
temperature, the nitrogen bases are considered completely detached and the disruption of π 
system by the peptide skeleton takes less important. 
The proteins that recognize DNA do not interact with the PNA of the same nucleotide 
sequence, probably due to the lack of electrostatic interactions with the skeleton [136]. 
The hybridization PNA-nucleic acid is very sensitive to mismatch, in fact it is seen that 
the PNA bind preferentially to the complementary sequences; more weakly to those 










Fig.6 DNA and peptide nucleic acid: comparison between th  two different structures.  
 
1.3.2 PNA anti-gene 
The PNA is able to block gene expression through two mechanisms: 
• inhibition of transcription by binding to DNA (anti-gene strategy) 
• inhibition of translation by binding to mRNA (anti-sense strategy) 
The PNA antigen can stop the transcription process through their ability to invade the 
double helix of DNA and form a complex or a stable triplex structure. The PNA can bind to 









also be designed to bind the binding sites for transcription factors within the internal 
promoter, thus inhibiting the binding and action of c rresponding transcription factors [141]. 
The PNA against the promoter region can form a stable PNA-DNA complex that reduces the 
access to the DNA polymerase. The PNA-DNA complexes located far downstream of the 
promoter, can also efficiently block progression of p lymerase and transcription elongation 
and so produce truncated mRNA. The triplex PNA2/DNA stop transcription in vitro and are 
able to act as an anti-gene agent [142].  
In physiological saline conditions, the binding of PNA to super-coiled plasmid DNA is 
faster than the linear DNA [143]. This result is based on the fact that usually the 
transcriptional active chromosomal DNA is negatively super-coiled, and it can act as a better 
target for the binding of PNA in vivo. In addition it was shown that the binding of PNA to 
double-stranded DNA increases as the DNA is transcribed. 
The anti-gene strategy has the advantage, compared with antisense, to block the gene of 
interest even before it is transcribed: the PNA anti-gene can then be used at lower 
concentrations and shows a stronger inhibitory effect and prolonged over time compared to 
antisense [91].  
 
1.3.3 Uptake of PNA in vitro and in vivo 
The poor cellular uptake of PNA is considered the biggest obstacle in the potential of 
using the PNA as therapeutic agents. 
Using phospho-lipid vesicles (liposomes) as a model f cell membranes, Wittung and 
colleagues have demonstrated that the PNA has a speed of efflux from liposomes very slow (t 
½ of 5.5 and 11 days for two PNA of 10 nucleotides) [144]. From these experiments it is 
concluded that the entry of PNA into cells, by passive diffusion, is very slow. In other studies, 
has been shown that the PNA's entry in some cells and cell lines is too slow or even 
undetectable.  
In contrast, several groups have found that some cells ar  subjected to the entry of PNA, 
suggesting specific transport mechanisms for these mol cules [139]. It has been reported, in 
studies both in vitro and in vivo, that the PNA enter in mouse neuronal cells. In cultured 









expression of target genes, depending on the time and dose [145]. The uptake by neurons is 
also been shown in vivo. When injected into mouse brain, the PNA are able to decrease the 
expression of target gene activity, showing an antise se activity [146]. In addition, several 
groups have shown that, injected intravenously or intra peritoneum, the PNA can cross the 
blood-brain barrier and enter neurons, causing an antisense reply [139] [145].  
So the uptake of PNA appears to depend on cell type. In fact, it is seen after using high 
concentrations of PNA and long incubation times, it is possible to induce the uptake of PNA 
even by myoblasts, fibroblasts, lymphocytes and other cell types [142] [147]. 
To facilitate the uptake of PNA in eukaryotic cells have been proposed several methods:  
• permeabilization of the cell membrane with lisolectina [140] or detergents like Tween 
[148];  
• temporary permeabilization with streptolysin O [149];  
• PNA modification of hydrophobic motif [150];  
• use of transport vesicles such as liposomes;  
• PNA conjugation to receptor ligands or antibodies that induce endocytosis receptor-
mediated of their respective conjugates [151];  
• conjugation with peptides that promote translocation across the cell membrane [152] and 
targeting specific compartments [153]. The class of Cell Penetratine Peptides, CPP, is 
growing rapidly. Different studies have shown that penetratine [154] [152] are able of 
carrying the PNA through the cytoplasmatic membrane in eukaryotic cells. In addition 
constructs PNA-NLS (nuclear localization signal) increase cellular uptake of PNA and 
facilitate their transport from cytoplasm to nucleus [153]. The anti-gene PNA conjugated with 
the NLS peptide, designed for selective inhibition of MYCN gene in human neuroblastoma 
cells (GI-LI-N and IMR-32: MYCN amplified and over-xpressed, SJ-N-KP and NB-100: 
MYCN not amplified and low expressed), bring inhibition of transcription, inhibition of 
protein expression, inhibition of cell growth: the c lls are stopped in G1, and they should then 
undergo apoptosis. Its inhibitory effect against the MYCN gene transcription, is highly 
specific and selective [155].  









PNA/ DNA chimera  with cationic lipids [156];  
• micro-injection [138], electroporation.  
 
1.3.4 Therapeutic applications of PNA anti-gene 
The high stability at the cellular level, due to their structure and their lack of charge, and 
the ability to define are fairly stable with DNA, provide to the peptide nucleic acids a 
significant therapeutic role in treating several tumors. PNA directed against the early-genes 
E6-E7 of human papilloma virus, responsible for about 100% of cervical tumors, restore the 
normal function of genes such as p53 and pRB (normal targets of the virus) and attach a 
normal phenotype to HeLas cells [157]. 
Further therapeutic evidence has been reported in prostate carcinoma cells where PNA 
directed to the c-MYC gene inhibit the transcription and translation at 24, 48 and 72 hours in 
addition to defining a decrease in cell growth [158].  
And more selective inhibition of Eµ enhancer regions responsible of the over-expression 
of c-MYC in Burkitt lymphoma lines (BL) defined cellu ar cycle arrest in G1 phase, and 
blocking the expression of that gene [159]. 
The effectiveness of PNA anti-gene was also tested in different cell lines of 
neuroblastoma. Sun and colleagues have shown that these third-generation antisense 
conjugated to somatostatin analogs (SSA), are able to p netrate the nuclear area, to selectively 
inhibit the expression of MYCN in IMR-32 lines and stopping the growth [160].  
Recent studies have also shown that PNA conjugated to specific nuclear localization 
sequences (NLS) define the most evident effects in MYCN amplified neuroblastoma cell lines 
compared to not-amplified. The cell cycle arrest in G1 phase is in fact more pronounced in 
lines such as IMR-32 and GI-LI-N (80-90%) compared with lines containing fewer copies of 
target gene (50-60% for SJ -N-KP and NB-100). 
This ratio is also reflected in the decrease of the expression of MYCN to 24, 48 and 72 
hours and the concomitant entry into apoptosis [155]. 
The evident therapeutic results obtained from in vitro studies have laid the foundations 









Pharmacokinetic studies have shown no toxicity of this molecule in the long and short-
term in mouse model of Burkitt's lymphoma; the molecu  also remains in the tissues, 
especially in the tumor for at least 600 minutes in vitro at concentrations that inhibit BL 
[161]. 
 
1.4 Chemotherapic compounds 
The chemotherapy drugs identify all those drugs whose chemical structure and physical 
properties are useful in the treatment against the majority of tumors present. 
These substances may be synthetic or produced by strains of microorganisms, possess 
selective toxicity and infectious agents to cancer cells and absence (or reduced) toxicity to 
normal cells of the human organism. 
The chemotherapeutic agents act causing death cell in several ways. Some of these 
drugs are naturally occurring compounds, identified in several plants, and some are synthetic 
chemicals. Anti-neoplastic agents are divided into specific categories based on their 
mechanism of action.  
In the following paragraphs we will analyze three classes in particular: alkylating agents, 
inhibitors of the mitotic spindle (SPs/MIS) and inhibitors of topoisomerase II. 
Recent studies have demonstrated the high efficacy of these drugs toward more or less 
aggressive forms of neuroblastoma. In particular, in vitro studies have shown as the apoptosis 
induced by these drugs and alterations in cell cycle are directly related to levels of MYCN 
amplification [163] [164]. 
 
1.4.1 Alkylating agents  
The term alkylating agents comprise compounds that have the ability to become strong 
electrophiles, thus interacting with nucleophilic groups (phosphate groups, amino, sulfhydryl, 
hydroxyl, carboxyl, imidazole) alkylating proteins and nucleic acids. Crucial importance has 
the cytotoxic effect related to the association of these drugs with DNA. The reaction that leads 
to the formation of stable drug-DNA complex (and / or protein) is schematically divided into 









• activation  
• nucleophilic attack  
During activation, the alkylating agent is activated by cellular metabolic processes to 
form an interim net positive charge. Once activated, he compound is able to interact with a 
number of groups which have a high electron density (phase nucleophilic attack). 
The main target of the alkylating agent is DNA; thechemical structure determines the 
degree of alkylation of various nucleophilic groups found in the nucleic acid molecule. In 
addition, both the structure and the charge of alkyl ting agents affect the specificity sequence 
of alkylation.  
 The alkylation of DNA bases leads to various physiological changes such as base-
pairing errors and subsequent mutations during replication; chemical injury and subsequent 
excision of bases, formation of covalent bonds within a filament and / or between filaments of 
DNA matched, stable ties with the associated proteins. In addition to altering the functions of 
nucleic acids, the chemical alteration of cellular proteins leads to changes in different 
enzymatic functions, including those responsible for DNA repair. 
These agents do not distinguish between cells in the middle of the cell cycle and in 
quiescent cells (Go phase), however, they are more toxic to rapidly proliferating cells. They 
are used to treat, in combination with other compounds, a wide variety of solid tumors and 
lymph [165] [166] 
Cyclophosphamide 
It is an anti-neoplastic agent belonging to the group f nitrogen mustards, containing a 
cyclophosphamidic group, is used in the treatment of many forms of cancer, largely as an 














Its activation involves enzymatic reactions by cytohrome P450, which define the active 
form (idrossi-cyclo-phosphamide) ionizing the chlorine. However, the intermediate more 
reactive is mustard phosphoramidates with a capacity to alkylate nitrogen N7 DNA of the 
guanine causing:  
• Alterations in the genetic code: the altered structure of guanine causes abnormal GT pairs  
• Broken imidazole ring of guanine  
• Depurination DNA for release of a guanine residue and subsequent collapse of the 
propellers of the desossinucleic acid 
• Cross-link of a pair of molecules of guanine 
Recent studies have placed the emphasis on the immuno odulatory effects of 
cyclophosphamide. This drug imposes alterations in lymphocyte populations of T-type 
determining the decline. These properties of cyclophos hamide, a potent immunomodulator 
therapies often used prior to bone marrow transplantatio . 
Cyclophosphamide is also widely used in the treatmen  of lupus heritematosus, various 
lymphomas, in care of gromerulonefriti in combination with glucocorticoids and azatriopina 
[165] [166] [167].  
Cisplatin and carboplatin 
Compounds of the class of alkylating similar, in fact, have the same function of normal 
alkylating agents does even not possessing alkyl groups. 
Cisplatin has a structure consisting of two labile ligands, two chlorides, and two inert 
binders, two amines; both in cis position. Carboplatin has instead a motif CBDC (bidentate 
cyclobutane dicarboxylate), which gives more stability to the compound (Fig.8) 









The diversity at the structural level between the two molecules is evident in the 
processes that define the training compounds chemically active. 
Once entered into the cell due to a lowering of the concentration of chloride (20 mM), 
cisplatin undergoes strong hydration in fact, becomes net positive charge and must be made to 
interact with nucleophiles. 
Carboplatin instead once entered in a cellular compartment can generate the reactive 
intermediate through hydration process (such as cisplat n) or by activation by a nucleophile.  
The main target is the DNA: both compounds may in fact contact two nucleotides of the 
same strand (intrastrand crosslink) or different strands (interstrand); in addition it can define 
DNA-protein crosslink. The most frequently cited is the intrastrand crosslink between two 
adjacent guanine [154]. Cisplatin and carboplatin in fact contacted the N group in position 7 
by defining a two-purine intrastrand crosslink 1.2 (GGA) or 1.3 (GAG). Other interactions, 
however, have to be taken into consideration: mitochondrial DNA, actin (shift in 
composition), phospholipids and phosphatidylserine (Jameson and Lippard 1999). The 
crosslink format involves a folding of the DNA, with exposure of the minor groove to the 
hooking of different proteins [165] [166] [168] [169]. 
Both compounds are broad spectrum in the treatment of ovarian tumor, metastatic 
testicular cancer in combination with bleomycin vinblastine, and ovarian cancer in 
combination with cyclophosphamide. 
Cito-toxicity  
         The alkylating compounds are cell cycle non-specific drug, thus causing damage to cell 
cycle phase-regardless, in particular the cross-links formed are mostly in G1 and G2 phases of 
the cell cycle. Alterations in DNA structure result in the block of the cell cycle through 
specific checkpoints in G1/ S and G2/M: in fact thecell tries to remove such alterations by 
specific repair mechanisms before to entry into S and M phase. The arrest in G1/S and G2/M 
is the result of a number of factors that recognize the damage (ATM/ATR), define the onset of 
specific pathways (CHK1, CHK2) and culminate in theactivation of p53 and the inhibition of 











At this point, the cell attempts to repair the damage through various mechanisms such as: 
• BER (Base Excision Repair), 
• NER (Nuclear Excision Repair), 
• MMR (Mis Match Repair), 
• HMG (High Mobility Group proteins). 
Where such errors persist in the genome sequence the apoptosis is triggered.  
In the case of cisplatin it has been shown that the alleged intrachain 1,2-d (GpG) is removed 
by excision repair mechanism [169]. This adduct formed in smaller quantities, it is removed 
more easily while it is uncertain whether the alleged interchain also be removed from this 
system. However, the initiation of the apoptotic cascade sees as fundamental responsible the 
class of HMG proteins. This fact suggests that adducts formed by cisplatin are intercepted by 
these proteins which, when linked to, prevent a shelter by the NER Mechanisms. This leads to 
a prolonged cell cycle arrest and subsequent cell death.  
 
1.4.2 Mitotic spindle inhibitor 
Vincristine 
Anticancer drug is derived from the Catharanthus roseus plant, also known as common 
“vinca rosea”. Vinca alkaloids are defined as drugs in this class work by blocking the 

















Belonging to the class of inhibitors of the mitotic spindle (SPs/MIS) vincristine is 
considered a cell cycle specific drug: its action involves in fact the molecules of tubulin (α
and β) deputies to the formation of the mitotic spindle useful for the migration of 
chromosomes during mitosis [165] [166]. In particular, the drug has the peculiarity of 
intercalation between the α and β tubulin dimers during the formation of microtubules by 
defining reversible bonds with a frequency of 2 molecules per heterodimer formed vincristine 
[171]. It has been shown that high concentrations of drug has the appearance of micro tubular 
crystals [171]. The cytotoxic action of vincristine in the first instance involves a failure to 
block the metaphase mitotic spindle formation and missed snapping kinetochores, with 
subsequent initiation of checkpoint the mitotic spindle.  
 Checkpoint determines the block in anaphase with selective inhibition of the promoting 
complex of the anaphase (Anaphase Promoting Complex APC) by Mad2 [171]. The block in 
anaphase leads to events of mitotic death (through the apoptotic cascade) or events of mitotic 
death after they see the formation of cells from the altered genomic content (polyploidy), 
intended to succumb [171]. Although some studies have shown high levels of caspase-3 after 
the block of cells in anaphase the mechanism that connects this block to a subsequent 
triggering of the apoptotic cascade is still unknow. Vincristine is currently used in treatment 
in non-Hodgkin's lymphomas, acute lymphoblastic leukemia in the treatment of Wilm's 
tumors, and occasionally as an immunosuppressant in cases of thrombocytopenia.  
 
1.4.3 Topoisomerasi IIα inhibitor 
       Etoposide (VP-16) 
      Etoposide is a semisynthetic derivate of the vegetal alkaloid podophyllotoxin responsible 
for inhibition of an essential enzyme for structural maintaining of DNA: mouse isomerase II α 
(α Topo2). It induces the formation of a ternary complex DNA-drug Top2-α disrupting the 



















Fig. 10 Etoposide structure. 
 
Topoisomerase II defines in fact a break in both strands of DNA and, through its 
tyrosine residues that contact covalently the residues at the 5' of DNA [173], is responsible for 
supercoiling desossimucleic acid. Plays a direct role in S/G2 phase of cell cycle since it leads 
to condensation and segregation of chromosomal structures [173].  
The drug (Fig. 10) involves the inhibition of the enzyme through steric hindrance (direct 
entry to the cleavage site that the enzyme has created),  triggering the following apoptotic 
cascade. The VP-16 is sterically tolerated in the cleavage site and its activity is directly 
proportional to the concentration of ATP present. Apoptosis is triggered by the persistence of 
a DSB [172]. The formation of an irreversible complex that become so after cutting the loop 
formed by the enzyme-VP-16 by nucleases, triggers a process of apoptosis via the extrinsic 
Fas-FasL [174]. It's also reported that interactions f Top2 α with the Rb protein are altered as 
a result of the use of inhibitors of the enzyme itslf [173]. 
       Etoposide also involves inhibition of Topoisomerase I by an indirect mechanism: the 
drug, binding to Top2 α, triggers the apoptotic cascade through deregulation of BCL-2, an 
important anti-apoptotic factor, hence activation of effector caspases (9-3), alteration of 
mitochondrial potential and the formation of toxic oxygen reactive inducing the block of 
Topoisomerase I. The blockade of this enzyme only requires further trigger the apoptotic 
cascade that amplifies the cytotoxic effect of the etoposide [172]. 









sarcoma, lung cancer, testicular cancer, lymphoma, non-lymphocytic leukemia and 
glioblastoma multiform, and of course neuroblastoma. It is also administered to patients 
before bone marrow and stem cells transplants. 
 
1.5 Gene targeting by single-stranded DNA 
oligonucleotides  
 
      Gene targeting by single stranded oligodeoxyribonucleotides (ssODNs) is a new 
technique that gives the possibility to introduce a site-specific sequence alterations in the 
genome. This tecnique was created in the group of Pr f. Hein te Riele at the Netherlands 
Cancer Institute and permits to generate subtle mutations in the genome of mouse embrionic 
stem cells, and also use this cells to create a mouse mutant [174]. 
Strategies based on homologous recombination require the design and costruction of a 
targeting vector and multiple round of selection and clonal purification of modified cells. 
Oligo targeting strategy is an alternative approach to introduce subtle gene modifications into 
mouse genome without affect the genomic organization of the target locus. This tecnique 
makes use of short single stranded DNA oligonucleotid s that are identical to the target gene 
except for the codon to be modified.  
DNA mismatch repair (MMR) system suppress the effici n y of gene targeting single 
stranded DNA nucleotides in mouse embryonic stem (ES) cell but inactivation of the MMR 
system also if improved the targeting frequency several fold, it could not be used due to the 
mutator phenotype associated with constitutive MMR deficiency [175]. In te Riele group they 
have seen that transient down regulation of the MMR gene Msh2 allowed effective 
substitution of four adjacent nucleotides in wild-type ES cells. It is not possible introduce 
single mutation with Msh2 gene transient inactivation because single substitution were still 
suppressed by 10% of residual MSH2 activity. Instead tr nsient suppression of MLH1, a 
downstream MMR gene, made cells permissive for all nucleotide substitutions ranging from 
one to four nucleotides. Although MLH1 knockdown resulted in some what higher mutation 
frequencies than MSH2 knockdown, the ssODN-modified ES cells retained pluripotency and 
could contribute to the mouse germ line [176]. The basal mechanism of ssODN-mediated 
gene targeting is not yet fully understood but the proposed model sees ssODN annealing to its 









regions present during DNA synthesis may enhance ssODN annealing. The possibility to site 
specifically alter endogenous genes may make ssODN-mediated gene targeting a possible tool 
for therapeutic applications. 
 
1.6 Murine models of neuroblastoma  
An obligatory step in the process of drug discovery r gards animal testing. The models 
described here identify what is the next step after an in vitro testing and the analysis of a 
molecule in a biological system more complex than cellular, more human-like: here we are 
talking about in vivo study. The use of animal models in preclinical studies appears to be the 
approach best suited not only for drug discovery but also for the identification and study of 
potential targets at the base of the tumor of interest.  
A good preclinical model must: 
• Give a faithful reproduction of the main biological characteristics of human cancer of 
interest  
• Allow an estimate of the molecular and cellular events associated with tumor growth and 
metastasis  
• Adequately replicate the difficulties associated with the location of primary tumors and 
metastasis  
• Allow objective and quantitative estimate of the endpoint associated with therapeutic 
response  
• Must be reliable, accessible, reproducible, easy to administer  
All mouse models have most of these characteristics, but they show also some limits 
[177]. For this reason it is necessary to use different  models.  
 
1.6.1 Transgenic models 
The term transgenic was coined in 1981 by Gordon and Ruddle [178] to describe an 
animal whose genome is introduced into an exogenous gene; in the 80s the term was extended 









the genome and production of chimeric and knockout mice, in which one or more genes are 
selectively removed from the genome. Today transgenic a imals are called the animals that 
have undergone any type of genetic specific modificat on [179]. 
To be able to insert a gene "exogenous" in an animal, so that it also will be expressed in 
its progeny, it is necessary to place as early as pos ible, and that is when the individual is 
made up of a few cells or even from oocyte just been f rtilized. Five different protocols are 
currently known to produce transgenic animals:  
1) the integration of retroviral vectors in the embryo at a very early stage; 
2) microinjection of DNA into the male pronucleus of a newly fertilized oocyte in 
vitro or in vivo; 
3)  incorporation in the embryo at a very early stage of embryonic totipotent cells 
(ES), genetically modified; 
4)  sperm-mediated gene transfer; 
5)  transfer of genetically modified nuclei in denucleated oocytes. 
After the change in embryo or gamete, the resulting embryos are matured in a pseudo-
pregnant female. 
The use of transgenic mice to study specific genes that cause the onset of determinate 
cancers is the best approach in spite of the use of x nograft animals in which human cancer 
cells are injected under the skin or in the site of origin of the human tumor. This choice 
depends by several reasons: the similarity of the histological tumor; the tumor is not usually 
immunogenic, but it develops in a immunocompetent mouse; the tumor develops 
spontaneous, and also it can present metastasis; it i  possible to study a wide range of cancers 
[180].  
 The use of recombinant DNA technology and transgenic models has provided much 
information about the genetic and molecular bases of human disease, in my field of interest 
the TH-MYCN transgenic model represents the best model to study neuroblastoma. This 
model has been created in 1997 by WA Weiss and his staff to demonstrate for the first time 
that over-expression of the MYCN proto-oncogene contributes to transformation of 









the proto-oncogene MYCN is amplified in approximately one third of patients with 
neuroblastoma, and it is correlated with advanced disease [83] [155] [156]. There are several 
experimental demonstrations of its oncogenic potential, and its role in modulating cell 
proliferation. The over-expression of MYCN combined with H-RAS mutated gene activation 
can transform rat embryo cells [83]; transgenic mice with over-expression of MYCN under 
the control of the enhancer of the immunoglobulin heavy chain develop lymphoid tumors 
[179] [180]. 
  The importance of TH-MYCN transgenic mouse model resides in the tissue specific 
expression of MYCN transgene: using Western blot analysis it is proven that the N-myc 
protein is present at high levels in the adrenal glnds, derived from the neural crest, from 
which originates the NB. There is also a marginal expr ssion in brain, heart, testis and spleen 
[88]. To achieve this result has been used the pTH-MYCN plasmid (Fig. 11), consisting of a 
fragment of 4.8 Kb of the rat Tyrosine Hydroxylase promoter, follow by the intron of the 
rabbit beta globin, the human MYCN cDNA and the sequence of the Thymidine Kinase gene 








Fig.11 Plasmid inserted into the TH-MYCN transgenic mouse 
 
The tyrosine hydroxylase promoter is responsible for tissue specific expression, as it is 
active in neural crest migrating cells, early in the development [183], it is also related to the 
direct state of the chloramphenicol-acetyl-transferas  in sympathetic ganglia and adrenal 









The Beta Globin intron has the function of enhancer of the expression, while the 
Thymidine Kinase gene serves to terminate transcription, because it contains a polyA 
sequence [88].  
The first TH-MYCN mice were created using the technique of the transgene injection in 
eggs of C57BL/6J and BALB/c strains. The generation s  obtained, containing 4 copies of the 
transgene, was serially crossed to the parental strin C57BL/6J for 7 generations. The F7 
females were then mated with castaneus males, as females castaneus rarely take care of their 
children [184].  Several lines of transgenic mice were then created.  
The clinical outcome varies from animal to animal and the tumor is localized in the 
chest or in abdomen. Mice with chest para spinal tumor appear emaciated, dispneic and bent; 
mice with abdominal tumor usually appear normal but the tumor may envelop other organs 
like adrenal gland, kidney, intestines. Sometimes th re is a paralysis of the lower extremities, 
and the tumor, as well as in the thoracic and abdominal positions, takes position along the 
peripheral nerve and also infiltrated into the spinal cord. Some animals show large metastases 
in liver, lungs and ovaries and other microscopic metastases to the lymph nodes, kidney, 
testes, brain and muscle.  
 In histology, the mouse tumors were similar to human tumor, and they show various 
degrees of neuronal differentiation: there are small round blue primitive cells, neuropil and 
ganglion cells; the tumors are positive for staining with the neuronal markers synaptophysin 
and neuron specific enolase NSE. The electron microscope also reveals the formation of 
synapses and neuro secretory granules. 
The Western Blot analysis shows that N-myc protein l vels, although varies from tumor 
to another, are equivalent to those found in human Kelly NB cell line, which has high levels 
of MYCN gene amplification [63] [88].  
The transgene dosage is directly associated with tumor incidence, number of individuals  
affected by the disease in a determinate period and tumor latency: in 100% of homozygous 
mice the tumor occurs in 4-7 weeks, while in 27-33% of hemizygous mice at 13-15 weeks 
[185] [186] [187]. The penetrance, the probability of a specific gene to be expressed, varies 
instead with the type of strain used for mating: crossing serially with the C57BL/6J strain 









Different studies on this transgenic model, have shown that there is no correlation 
between expression and dosage of MYCN transgene in murine tumors: Western Blot analysis 
reveals that some of the most high levels of N-myc protein expression are found in 
hemizygous mice tumors rather than in homozygous mice. Also there are not significant 
differences in the transgene dosage in homozygous and hemizygous mice tumors [173]. There 
is no correlation even between the expression and tumor latency: some of the most high levels 
of expression of the protein N-myc are in mice that develop cancer after a very large latency 
period (> = 13 weeks) [186].  
It was also shown that the process of gene amplification is specific for the transgene, in 
fact there are substantial differences in the dosage of murine MYCN between normal and 
tumor tissues [186].  
The chromosome analysis on murine tumors has shown that many of the most frequent 
genetic aberrations in human NB, are also present in TH-MYCN mouse model, suggesting 
that this model could be useful in the future to discover genetic abnormalities in mice, and 
identify parallel genes important in human disease [188]. Thanks to Comparative Genomic 
Hybridization (CGH) were identified gains on chromosomes 1 and 3, orthologous with the 
human region 1q, gains on chromosomes 11, 14, 17 and 18, and losses on chromosomes 5, 9, 
16, orthologous with regions 3p, 4p, 11q in human chromosomes and loss on X chromosome 
[88] [183] [187]. For example, the ortholog of human chromosome 17 is contained entirely in 
the mouse chromosome 11, in which we note a gain in 30% of murine tumors .  
 
1.6.2 Tumor xenograft models 
The term xeno-trasplantation derives from greek word ‘xeno’ that means "external" and 
provides the transplantation of cells, tissues or organs between different species of living 
beings. This technique differs from allo-transplantation, where donor and recipient belong to 
the same species. Few are the applications in the clinical field since there are many variables 
related to graft rejection by the immune system of the recipient, the size of tissues and organs 
and the average life of two different organisms.  
The xenograft however is more useful in research: since the mid-60's in fact the 









extensively studied with xenograft models. The development of tumor cell lines and primary 
human tumor cell lines in the last 25 years has paved the way towards the study of human 
cancer in other species as addressing the rejection of mass inoculated because of immune 
response. The used animals in fact have deficits in the immune system and mainly in the 
lymphoid component. The most commonly used strain are the nude mouse and the Severe 
Combined Immunodeficiency SCID mouse. Nude mouse does n t present thymus and for this 
reason is immunodeficiency in T-lymphoid cell and presents total loss of hair; the SCID mice  
present genetic alterations, these are reflected in lack of lymphoid B cells, T cells and natural 
killer cells (NK). 
The xenograft models are divided into:  
• Ectotopic xenograft models  
• Orthotopic xenograft models  
The main difference between two models is the point where the tumor is inoculated: the 
ectotopic model refers to a transplant under the skin, instead the term orthotopic defines a 
transplantation in the same anatomical location where usually the tumor arises.  
 This spatial difference shows then substantial discrepancies in enforcement. Ectotopic 
xenograft models used to validate the therapeutic ac vity of several drugs in preclinical phase 
were considered poorly predictive for poor results in the clinical phase [189]. The causes of 
these differences in healing are largely associated with the different location of the tumor 
mass formed as well as any differences related to the size of the mass in relation to different 
stages of tumor present in the clinic phase [189]. The orthotopic model from this point of 
view is more predictive in that the mass is formed in the animal is in the same position respect 
to human cancer. This allows to perform studies that are closest to those observed in a 
clinical, vastly reducing false positives associated with an experimental drug.  
 
1.6.3 Orthotopic xenograft neuroblastoma model 
The high occurrence of neuroblastoma in specific areas, 50% adrenal, 25% 
retroperitoneum, together with the need to obtain pre-clinical prototypes that faithfully 
reproduce the cancer has led to develop an orthotopic xenograft model in immunodeficient 









The current neuroblastoma orthotopic mouse model sees the injection of tumor cells 
obtained from biopsies of human primary tumors in retroperitoneal area or within the left 
adrenal gland. In both cases the animal is anesthetized, the first layer of the skin and 
secondarily the abdominal wall are cut. Approximately 2-2.5 x 106 cells are inoculated in the 
retroperitoneal area or in the adrenal gland [190] [191] [192].  
Reports show an incidence of 100%, a latency of 14-20 days approximately and 
metastasis formation in liver, spleen and kidney after 4 weeks in both sites of injection [190] 
[192]. 
The difference between locations reflects differences with regard to development of the tumor 
mass, the adherent junctions with the surrounding tissues and the localization of metastases. 
Recent studies have confirmed this difference [190]. Neuroblastoma NB69 cell line injection 
in SCID mice within the left adrenal gland and in its proximity has established the formation 
of a nodular tumor with size, latency and morphology identical for the two methods. 
However, the inoculation in the retroperitoneal area has defined:  
a) formation of a tumor adherent to the muscle toneof the animal;  
b) skin lesions similar to infections in 50% of the specimens at the site of incision;  
c) tumor nodules along the most abdominal wall. 
The usefulness of these models has been found not only in studies of tumor progression, 
angiogenesis, metastasis and invasive capacity [191] 2] [193] but also to test the activity of 
several drugs [192]. 
In fact orthotopic xenograft models have been used to validate the action of anti-
angiogenic drugs such as Bevacizumab or Bortezomib in neuroblastoma treatment [195] 
[196]. Such drugs like Bevacizumab reduct intratumoral vascularity powering the effect of 
traditional chemotherapeutic drugs [195]. 
Further studies highlight the usefully of the model for association studies between 
chemotherapy drugs: drugs such as vinblastine and rfamicina in combination would led a 













1.6.4 Transgenic model versus orthotopic model 
The transgenic and orthotopic models described above are the best alternatives present 
today for in vivo testing, but it is necessary analyze the similarities and the differences 
between models to see which is more reliable and pre ictive for subsequent studies to the 
stage in vitro.  
From a management perspective, orthotopic xenograft models show a greater simplicity 
compared with transgenic models and allow to obtain a large number of items representing 
the disease relatively quickly, compared to transgeic models characterized by redundant and 
highly useful analysis required to identify the correct genotype of the animals. This underlines 
the utility of orthotopic models in validation studies of drugs. It must also be considered the 
high invasiveness of the orthotopic model compared to the second model, the inoculation of 
cell lines in the body of the animal is a invasive surgery, this weakens the subject and the risk 
of infection is very high because of the host immune deficiencies.  
Both models define the formation of tumor mass, however, the transgenic model is 
more predictive, tumor formed represents perfectly the human tumor, with the same cellular 
and genetic heterogeneity; which makes possible a more complete analysis of interactions 
between tumor cells and host cells: studies of angiogenesis and interaction with the matrix 
cells are the evidence [197]. Orthotopic models instead use a specific human cell line whose 
profile is only isolated oncogenomic combinations of a wide range of genetic and epigenetic 
mutations that define a case report [197]. The presence of genetic alterations from the 
embryonic state in transgenic animal models makes th m useful for studying the early events 
leading to the development of the disease, for the design of potential therapies and prevention 
studies for target validation.  
The removal of oncogene of interest or the inclusion of specific mutations help 
understanding which genes are the real culprits of umor growth [197]. Should be emphasized, 
however, important limitations of the transgenic models related to differences between human 
and mouse genome, thus limiting their use in drug discovery processes [197]. The difference 









differences in telomere makes transgenic models do not fully appropriate for studies of this 
magnitude. In contrast to orthotopic xenograft models, however, they are highly predictive for 
the immune system, pharmacokinetics, dosage and toxicol gy [197].  
Despite substantial differences still are unable to distinguish which of the two models is 
better able to represent a clinical picture, in real they are complementary in some important 
aspects, such as the various applications in the process of drug discovery, as target validation 
and drug validation and the use of human cell lines or anatomical mouse compartments leads 
not to exclude either of them during pre-clinical exp riments. 
  
1.7 Molecular imaging  
The investigation of the molecular alterations present in many diseases is pursued 
through genetic testing, blood specific tests and histopathologic analysis. In addition, many 
diagnoses are made only after the onset of first symptoms and in such cases the disease state 
is just advanced. 
Therefore are needed new non-invasive methods for obtaining morphological and 
biochemical information for functional characterizat on of early molecular changes: for this 
reasons  Molecular Imaging techniques are needed. 
The term Molecular Imaging, coined in 1990, defines the visual representation, 
characterization and quantification of biological processes at cellular and subcellular level 
within living organisms "intact". 
Imaging systems more used are the X-ray computed tomography (CT), magnetic 
resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission 
tomography (PET), optical molecular imaging, which includes fluorescence and 
bioluminescence (BLI).  
 
1.7.1 Micro Positron Emission Tomography 
Positron Emission Tomography (PET) is a non invasive technique of Nuclear Medicine 
that allows reconstruction of the distribution of radiotracers from the interior of a living 









        PET was developed in 1970 [198][199], the pysical process behind the production of 
images with PET is the emission of a positron and a eutrino; the positron having mass equal 
and opposite charge compared to an electron, crosses the biological matter and then combines 
with an electron, before annihilating. The mass of the positron and of the electron is converted 
into two photons (radiation γ) emitted simultaneously along the same direction but in the 
opposite direction, and their direction of flight is measured using a set of detectors in time 
coincidence, placed around the subject [200]. Then t  signal is amplified by photomultiplier 
tubes, which transmit it to a computer, which will build a three-dimensional image.   
The advantage of these labeled molecules is that the isotope does not change the 
physiological behavior of the molecule so it does not alter the structure of its biochemistry. 
Most of the radioisotopes are generated inside the cyclotrons. A cyclotron is a particle 
accelerator, which includes a pair of metal electrodes positioned between the poles of a large 
electromagnet; a source of ions in the cyclotron geerates charged particles, usually protons, 
which are accelerated and, when reached a level of sufficient energy, are directed on a target, 
causing a nuclear reaction that eventually transforms the substance of the target in the 
aspected isotope. The radioisotope products are autom tically transferred to the target in 
radiochemistry modules in which are produced the radiopharmaceutical compounds.  
Most of the radiotracers has a short half-life and must be produced near the point of use, 
so the use of these isotopes is limited only to centers that have their own cyclotron. 
So that a radioisotope can be used as a PET radiotrcer must meet strict criteria: the isotope 
should not be easily dissociated from the molecule to which it binds, and this link should not 
alter the biological properties of the molecule itself as transportation or disposal; the tracer 
must be quickly eliminated from the blood and no target molecules, so that there is an high 
contrast between tumor tissue and adjacent materials.  
The radioisotopes are typically administered intravenously and the dose of radiation 
received is higher than that of a normal radiograph. The PET is emerging as a technique of 
molecular imaging for the superior specificity and accurancy in spite of common techniques 
of diagnostic imaging (TAC, MR), and the main applicat on areas are oncology, neurology 
and cardiology. 
For many years researchers have used small experimental animals as models for human 









these techniques have two main disadvantages: the post-mortem data collection, which fails to 
provide a real representation of the processes in vivo and the inability to manage longitudinal 
studies on the same subject. The use of Micro-PET allows studies of this magnitude. 
The creation of micro-PET scanners that could be reli d upon as the classic PET 
scanners for human use, has been a long and arduous pr cess, involving different practical 
issues, related mainly to the differences between ma and animal laboratory.  
The mouse, for example, is little more human than 3 orders of magnitude, weighing 20-
30 grams against 70 kg of an average man. Because of this difference in Micro-PET must 
have a very high spatial resolution and sensitivity as to achieve the same level of accuracy 
achievable with PET [201]. 
The small size of the animal also limits the amount of tracer used, whereas it should not 
affect the process being studied, for example, in Mcro-PET revealed that the ligand-receptor 
binding within cells, this parameter is satisfied when the tracer does not occupy more than 1% 
of free receptors [202].  
In almost all molecular imaging technologies, the subject must remain fixed throughout 
the acquisition of the image, to produce a correct image to define the proper uptake of the 
radiopharmaceutical compounds. Radiotracers such as 18F-FDG, for example, are also highly 
detected non-tumor areas with high glucose metabolism, such as the heart and muscles, 
increasing the chance of having false positives. As regards micro-PET studies is not possible 
that the animal remains motionless so voluntarily are used various forms of anesthesia [203] 
[204] [205] also to reduce the stress caused to the PET. It is important to understand the 
effects of anesthetics, in order to minimize them, as many studies have shown that the 
administration of anesthesia can compromise systems neuroreceptor. 
 
1.7.2 MicroPET applications  
The Micro-PET is used in various fields: 
• images of gene expression: as the use of GFP  as reporter gene in molecular biology, in 
PET it is used the PRG (PET reporter gene) expressing a PET reporter probe, which can tie a 
radiotracer [206]: the gene of  interest, put under th  control of the promoter of the PRG will 









proportional to the amount of protein expressed by the gene of interest. In basic research that 
allows to study non-invasively the expression levels of genes in transgenic models in vivo, 
and monitoring the effectiveness of any gene therapy studies in pre-clinical setting [207].  
• oncology: this is due to the large number of animal models avail ble (transgenic models, 
xenograft, knock-out.) [201]. There are many radiotracers used: 18F-FDG, FLT 3'-deoxy-3' -
[18F] fluorotimidina [208], labeled antibodies and fragments of antibodies [209]. 
• applications are still being investigated regarding the auto-immunity, tumor immunology, 
activation of T lymphocytes [201], longitudinal studies are carried out on glucose metabolism 
in the heart and brain of rats [210], studies on the cerebral dopaminergic system [211], studies 
on epilepsy [212] and rheumatoid arthritis  [213]. 
In this study two radiotracers are analyzed: 18F-FDG and 18F-DOPA. 
A                                                                B 
Fig.12 The radiopharmaceutical compounds 18F-FDG (A)  and  18F-DOPA (B). 
 
Fluorine-18  (18F) is an unstable isotope of fluorine, one of the most widely used tracer 
for conducting PET, CT-PET and SPECT scans. It presents a rather long half-life (t ½ = 109.6 
minutes) and chemical properties similar to hydrogen, it is usually replaced to hydrogen 
atoms in many natural molecules such as amino acids, arbohydrates, lipids, and a large 
amount of drugs.  
The 18F is used primarily in the formation of 18F-FDG (2-[18F] fluorine-2deoxy-D-
glucose) a precursor of glucose that follows its process of metabolism: after being injected 
into the blood it is transported within cells by glucose transporter and converted by the 
enzyme hexokinase to FDG-6-phosphate [214]. Unlike glucose, FDG has not the hydroxyl 









then remains trapped inside the cell, proportional to the rate of glycolysis. Its accumulation is 
then associated with the use of glucose, which is index of high cell metabolism [199]. These 
properties identify the 18F-FDG as a molecule useful in the monitoring of various forms of 
cancer. The tumor cells in fact have a high metabolic activity.  
 The 18F-FDG was used for the first time in the 80s in the study of tumors by Di Chiro 
and other [215] it was proved that the degree of malign ncy of brain tumors was related to the 
uptake of 18F-FDG. The first application of PET with 18F-FDG which is not the neuro-
oncology was instead in the study of lung cancer [216] [217]. PET with 18F-FDG is the first 
molecular imaging technique to be applied on a large scale to imaging study of brain, heart 
and tumor [218]. 18F-FDG, however, can not be used for some neoplastic diseases 
(particularly those with high differentiation and low growth rate) since burdened by too high 
share of false negatives. Moreover, it is no highly selective for tumor cells. Studies of this 
tracer have consistently revealed a high uptake for macrophages [219] [218] [220]. 
L-18F-DOPA is used in neurology to study metabolism, neurotransmission and cell 
processes. L-DOPA is the precursor for the neurotransmitter dopamine and radiolabeled L-
DOPA is taken up by dopaminergic terminals and becomes incorporated into the 
neurotransmitter. L-18F-DOPA can be used to examine the presynaptic distribution of stored 
neurotransmitter and it used to diagnosis and follow up of neuroblastoma and other Neuro 
Endocrine Tumors characterized by increased activity of DOPA decarboxylase.  It also has 
been used clinically in the study of Parkinson’s disease [221].  
 
1.7.3 Bioluminescent imaging 
The bioluminescence imaging is a reporter system based on an enzymatic reaction 
catalyzed by the luciferase protein, the enzyme that generates light thanks to oxidation of its 
substrate, D-luciferin, in oxiluciferin, in living systems [222]. 
In nature there are different bioluminescent system characterized by a specific enzyme 
system. The most used bioluminescent system in scientific research is the North American 
firefly luciferase (Photinus pyralis; FLuc), but several clones of luciferase were identifi d 
from jellyfish (Aequorea), from the sea pansy (Renilla), from corals (Tenille) and from 









Luciferase is an excellent marker for gene expression because it lacks post-translational 
modifications and has a half-life (t 1/2) in vivo of about 3 hours.  
 






The spectrum of light is between 530 and 640 nm with an emission peak at 562 nm. 
This emission spectrum, coupled to the optical prope ties of tissue, allows light to penetrate 
through several centimeters of tissue. In this way it is possible detect light emitted from the 
internal organs of small mammals that express the luciferase as reporter gene. The photons are 
detected by  a special Charge Coupled Device (CCD) camera that convert photons into 
electrons. The CCD camera spatially encoding the int nsity of the incident photons into 
electrical charge patterns to generate an image. This camera is controlled by a computer for 
image acquisition and analysis.  
The catalyzed luciferase reaction is a complex interaction between ATP, luciferin and 
oxygen, the exogenous substrate. The reaction occurs only in metabolically active cells, which 
contain the luciferase, because the reaction requirs the presence of ATP. The light signal 
intensity depends on various factors such as the level of expression of luciferase, the substrate 
concentration, the wave length of light generated, the sensitivity of the detector and the 
localization system of labeled cells inside the body. In general, the signal strength decreases 
10 times for each centimeter of tissue through [223].  
The BLI is widely used in cancer research for identifyi g metastasis and to measure the 
proliferation of tumor cells that express luciferase. Some studies done using HeLa 
luminescent cells injected into the tail vein of immunodeficient mice have demonstrated the 
utility of BLI in the early detection of lung metases. Similarly, other studies have shown 









disease in vivo. It has been shown that the detection of tumor cells in internal organs by BLI 
has a sensitivity at least equal to that of positron emission tomography (PET), also with 
respect to PET, which requires toxic and radioactive tracers, the BLI requires only 
administration of D-luciferin, non-toxic even in newborn pups [224].   
In conclusion, the BLI may be regarded as a powerful method of investigation and pre-
clinical diagnosis, however, quantitative analysis must be done with caution and require 
validation of each specific application.  
 
1.7.4 Transfection of cell lines throughout retroviral vectors 
The stable expression of heterologous genes in the mammalian cells can be reached by 
the use of recombined retroviruses.  
The most commonly studied and utilized retroviruses are those belonging to the 
Retroviriade subclass. This retrovirus typology is modified and it has lost its replicative 
capacity because it do not present some genes express within the wild type strain. They allow 
the stable integration of transgenes within the eukaryotic cells genome [225]. 
Retroviruses are defined as viruses whose genome is con tituted by a singular RNA 
filament of around 10 Kb of size and by a region ψ for the packaging. It includes three 
essential genes, gal, pol, envelope. They codify respectively the core proteins, the inverse 
transcriptase and the capside. 
Long Terminal Repeats (LTR) are placed to each edges and these sequences are implied 
in the integration phase. LTRs are divided in three regions: U3, R and U5. The 5’ R is defined 
as the initial signal sequence for the transcription phase in the 5' LTR, whereas the U3 region 
contains both the promoter and the enhancer element. Moreover, the U3 region contains the 
signal of poliadenilation. During the retrotranscription, the U3 region at the 3' LTR and the 
U5 region at the 5' LTR of the viral RNA are duplicated (Fig.13). Once the cell is infected, 
the RNA is retrotranscribed in a double DNA filament that entries in the nucleus and it is 
integrated in the genome of the host cell, expressing in this way the viral proteins. Simple 
retroviruses such as MLV are unable to cross the nuclear membrane and the infection is 






















Fig.13 Life cycle of retrovirus. 
 
The most common retroviral vectors are derived by MLV (Moloney Murine Leukaemia 
Virus), that is an amphotropic virus able to infect bo h human and murine cells. 
 In these vectors, viral genes are replaced by the transgene of interest, which is inserted 
between the LTRS downstream packaging signal and the promoter. They can also be added 
marker genes (such as neomycin) and alternative promoters of viral origin. 
The gag, pol and env coding regions are separated in o d stinct transcriptional units in 
order to decrease the risk of production of wild-type virus through recombination, and added 
with stable integration in cell lines that are called packaging cells. The packaging cells are 
able to generate a complete virion, but empty because they do not contain the sequence ψ and 
can not package the viral genome in the virion. Theviral vector instead contains the transgene 
downstream of ψ, and thus, if inserted into a packaging line, it produces a viral progeny which 
virion is provided by the packaging line and the genome is the recombinant viral vector 









The range of cells that can be infected by recombinant retroviruses thus produced, 
depends on the type of envelope protein in the virion. We can distinguish ectotropics 
retrovirus, which can only infect cells of rodents and anfotropics retrovirus, which infects 










Fig.14 Schematic representation of the genome of retroviruses and retroviral vector.  
 
 
The choice of vector system is highly dependent on target cells. Generally, vectors 
derived from MLV are easier to produce and, to date, r  available in a wide range of 
packaging cells. However, infection by these viruses is extremely low in quiescent cells or 
low growth rate and therefore should be used only i cells with high growth rates such as 
tumor cells. 
 
1.7.5 MicroPET versus bioluminescent imaging 
The main difference between micro PET and bioluminescence lies in the portion of the 
electromagnetic radiation spectrum used, which affects the performance of each methodology. 
In fact, the high penetrating power of γ-rays created by the phenomena of annihilation in the 









quantification of the signal at the level of the deep r anatomical structures than the 
bioluminescence. However, both techniques have high sensitivity coupled with excellent 
spatial and temporal resolution.  
Another difference consists in the type of molecular probe used. MicroPET uses 
radiolabelled probes: probes that consistently produce the signal through the decay of 
radioisotopes; while the bioluminescence uses active probes: probes that emit a signal only 
after interaction with their target.     
                                                                                                                                                                                                                               













Fig.15 Comparison between the two different probes: a radionuclide probe for microPET experiment and a 




All probes must have some basic characteristics: biocompatibility, ability to cross 
biological barriers, the possibility of signal amplification in vivo. They must consider some 
important pharmacokinetic properties such as metabolism, excretion / reabsorption, urine 
excretion, cytotoxicity. The probes should be stable and especially should not be able to elicit 
the immune response. 
 
Regardless of the differences inherent in each method, t e investigator should consider 









The specificity of the micro PET comes from the ability to mark a particular 
radioisotope molecule without perturbing its biological function for the small steric hindrance. 
However, because of their short half-life, it require to have a cyclotron on site or nearby. In 
addition, the radioactivity of the tracer could have effect on the patient, limiting its use. The 
sensitivity of micro PET is equivalent to 10-100 times the SPECT, CT and MRI and 
thisresults from the use of coincidence of counts of photon collimators and the ability to 
correct the resulting loss of signal due to attenuation of the photons. However  you need a 
large number of crystal detectors. 
 The microPET allows to obtain sections of images and it is a translational method in 
fact, using the same technology in clinical practice, the transition between the preclinical and 
clinical applications is faster, reducing the time needed to transfer information in an other type 
of analysis.  
        One of the most important application of microPET is the oncology. With micro PET It 
is possible to monitor tumor progression during time and in the same subject characterizing 
the level of metabolism, hypoxia, perfusion, cell proliferation in tumor. 
Micro PET does not give anatomic information and some radiotracers are aspecific. For 
example,18F-FDG accumulates not only in cancer cells but also in sites of chronic 
inflammation or in high metabolic active organs like heart, also its uptake is not related to the 
tumor increase speed and for this reason the data must be interpret by expert investigator. 
Micro PET allows pharmacokinetic and pharmacodynamic studies for drug development also 
if it is a expensive technology. 
Unlike the micro PET, bioluminescence has low running cost, there is not the problem 
of penetration of the beam of excitation in the tissues and there is no source of intrinsic 
autofluorescence so there are not false positive signals. The use of luciferase as a marker 
represent an advantage because it lacks post-translatio al modifications and it has a half-life 
in vivo of about  3 hours. Thanks to the short acquisition mes it is possible to monitor 
different animals in the same analysis and also monitor biologic process during the time. The 
instruments analyze all the body of the animal given a complete view of all tissues and 
organs. 
The disadvantages of this technique derive from two fundamental properties of light in 
tissues that depend on the wavelength: the diffusion and absorption. These affect the 









light transmission  because of the oxy hemoglobin and deoxy hemoglobin absorption [228]. In 
vitro it has been estimated that the reduction of bioluminescence signal is approximately 10 
times for each centimeter of tissue analyzed. Moreover the reaction of luciferase requires the 
interaction with a variety of molecules including oxygen, ATP and luciferin, if any of these 
elements are not enough present in the tissue, the emission of light can not represent the real 
activities of luciferase [226].  The correlation and the application of the results are difficult 
because there is no equivalent in clinical practice.  
Although micro PET and  bioluminescent imaging present limits, they can be 
considered complementary and they provide a multimodal approach to research in order to 











Materials and methods 
 
2.1 Chemicals 
The PNA was designed as homologous to a unique sequence of the noncoding 
(antisense) strand in exon 2 of MYCN (bp 1,650-1,665: 5’-ATGCCGGGCATGATCT-3’; 
Genbank accession no. M13241). This PNA antigene (PNAs), which is complementary to a 
unique sequence in the DNA strand, was designed to directly inhibit mRNA synthesis. To test 
the specificity of the activity of this PNAs, a misatched PNA (PNAmt) was also designed 
containing a 3-base substitution (5’-GTGCCGAGCATGGTCT-3’). Specificity was verified 
using the BLAST homology program. All the PNA molecules were covalently linked to their 
COOH terminus with a nuclear localization signal (NLS) peptide (PKKKRKV) to mediate 
transfer across the nuclear membrane [229]. Synthesis, purification and characterization of the 
PNAs and PNAmt was made by our laboratory as described [155]. 
Vincristine, etoposide, carboplatin, cysplatin and isoflurane (Aerrane) were purchased 
from Baxter Health Care Pty Ltd (Lessines, Belgio).  
The pSUPER vector (Sigma–Aldrich, Zwijndrecht, Netherlands) contains a puromycin 
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of MLH1 gene, involved in mismatch repair system (kindly provided from H. Te Riele, NKI, 
Amsterdam, The Netherlands). 
Unmodified 35-mer single-stranded OligoDeoxyriboNucleotides (ssODNs) were 
designed to introduce a single base mutation in mouse MYCN sequence, in this way the 
human target sequence of PNAs would be also present in the mouse MYCN DNA sequence. 
Sequence sense ssODN (5’-GCGTCCACCATGCCGGGCATGATCTGCAAGAACCC-3’) is 
complementary to the transcribed strand except a single mutation in the centre (C versus G) of 
the oligonucleotide flanked by 17 matching nucleotides on each sides.                             
 Anti-sense ssODN (5’-GGGTTCTTGCAGATCATGCCCGGCATGGTGGACGC-3’) 
has opposite polarity and it is complementary to the non transcribed strand but it introduces 
identical base change. Both ssODNs were ordered at Sigma–Aldrich (Zwijndrecht, 
Netherlands). 
 
2.2 Cell lines 
 For in vitro proliferation assay, chemotherapeutic treatment and orthotopic mouse 
models I used the following adherent neuroblastoma cell lines: 
IMR-32, SK-N-BE(2)c (kindly provided from G. Della Valle, Department of Experimental 
Evolutionary Biology, University of Bologna, Italy); IMR-5 (from M. Schwab, Department of 
Tumor Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany); Kelly (from Dr. 
R.A.F. MacLeod, DSMZ, Braunschweig, Germany) characterized by amplification and over-
expression of MYCN [230] MYCN-unamplified/low-expressed SJ-N-KP (kindly provided 
from P. Rocchi, CIRC, University of Bologna, Italy); MYCN-unamplified/unexpressed GI-
CA-N (from F. Pastorino, Gaslini Children’s Hospital, Genova, Italy). The human NB cell 
lines IMR-32, Kelly, SJ-N-KP and GI-CA-N were obtained from different tumors at diagnosis 
and present p53 gene wild type, while SK-N-BE(2)c was obtained from a tumor relapsed after 
chemotherapeutic treatment and presents multi-drug related p53 mutations. NHO2A (from W. 
A.Weiss, Department of Neurology, University of California, San Francisco) is a cell line 
derived from homozygous TH-MYCN mouse tumor characterized by amplification and over-
expression of cDNA human MYCN. Human cell cultures were maintained in RPMI-1640 
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Italy), 1% L-glutamine 2mM (GIBCO-Invitrogen, Carlsbad, CA), 1% non-essential amino 
acid solution 0.1 mM (SIGMA-ALDRICH, Milwakee, WI). For murine cell line RPMI-1640 
was supplemented with 20% FBS, 1% sodium pyruvate 1mM (GIBCO-Invitrogen, Carlsbad, 
CA) and 0.07% β-mercaptoethanol 10nM (Merck, Darmstadt, Germany). 
 
 
 Species Loc. Age Sex MYCN INSS 
IMR-32 Homo Sapiens A1 12 month M Amplified/ over-
expressed 
4 
IMR-5 Homo Sapiens   - Amplified/ over-
expressed 
4 
SK-N-BE(2)c Homo Sapiens A1 22 month M Amplified/ over-
expressed 
4 
Kelly Homo Sapiens - - - Amplified/ over-
expressed 
4 
SJ-N-KP Homo Sapiens UNK3 5 year - Single copy/  
low-expressed 
- 
GI-CA-N Homo Sapiens AG2 9 month F Single copy/ 
unexpressed 
4 
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Cell lines were subcultured at 37°C / 5% CO2 weekly, cells being detached from the 
monolayer with citric saline (135 mM potassium chloride (SIGMA-ALDRICH, Milwakee, 
WI), 15 mM sodium citrate (SIGMA-ALDRICH, Milwakee, WI)). 
The generation of luciferase positive NB-cell lines required Phoenix cell line (Phoenix 
Retroviral Expression System, Orbigen). Cell culture was maintained in DMEM medium 
(SIGMA-ALDRICH, Milwakee, WI) supplemented with 10% FBS (Euroclone, Pero, Milano, 
Italy), 1% L-glutamine 2mM (GIBCO-Invitrogen, Carlsbad, CA), 1% streptomycin/penicillin 
antibiotics (GIBCO-Invitrogen, Carlsbad, CA).  
The oligonucleotide-mediated gene modification was performed on 129/Ola- derived E14-
IB10 Murine Embrional Staminal Cells (mESC) [231]. The cell line was cultured on Murine 
Embryonic Fibroblast (MEFs) feeders in Glasgow minial essential medium (GIBCO-
Invitrogen, Carlsbad, CA), supplemented with 10% FCS (Fisher Scientific, Thermo Scientific 
HyClone, Loughborough, Leicestershire), 1mM sodium pyruvate (GIBCO-Invitrogen, 
Carlsbad, CA), non-essential amino acids (GIBCO-Invitrogen, Carlsbad, CA), 1mM β-
mercaptoethanol (Merck, Darmstadt, Germany) and 1000 U/ml of leukaemia inhibitory factor 
(LIF, GIBCO-Invitrogen, Carlsbad, CA). For transfections and puromycin selection, ES cells 
were cultured onto gelatin (SIGMA-ALDRICH, Milwakee, WI)-coated plates in Buffalo rat 
liver cells -conditioned medium [231]. The cell lines were cultured at 37°C / 5% CO2, cells 
being detached from the monolayer of MEFs and from the BRL medium with 10x and 2x 
Trypsin (TVP), respectively. TVP was prepared with DPBS pH 7.4 (GIBCO-Invitrogen, 
Carlsbad, CA), EDTA 40 mM (GIBCO-Invitrogen, Carlsbad, CA), Chicken Serum 1% 
(GIBCO-Invitrogen, Carlsbad, CA), Trypsin 2.5% (GIBCO-Invitrogen, Carlsbad, CA). 
 
2.3 Proliferation assay 
To assess the cytotoxic and proliferative effects of PNAs and PNAmt at 24, 48 and 72 
hours and chemotherapeutic drugs at 72 hours I used the Adenosine TriPhosphate monitoring 
system based on firefly (Photinus pyralis) luciferase (ATPliteTM Perkin Elmer, Waltham, MA, 
USA). The experiments were performed on 96-well microplate adding 50 µl of mammalian 
cell lysis solution to a 100 µl cell suspension. After 5 min in an orbital shaker at 700 rpm, I 
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and 10 min at dark the emitted light was measured with Infinite F200, TECAN. The measured 
luminescence is proportional to the ATP concentration. ATP is a marker for cell viability 
because it is present in all metabolically active cells and the concentration declines rapidly 
when the cells undergo necrosis or apoptosis. (ATPLT-0408 / REV. F). Each experiment was 
performed at least four times and the cell lines were seed 24 hours before the experiment to 
allow cell adhesion. 
  
2.4 Generation of luciferase-positive neuroblastoma 
cell lines 
The pMMP-LucNeo vector (Fig.16), a generous gift from Prof. A. Kung (Harvard 
University, Boston) was used to transform in XL1 E.coli competent cells (Agilent 
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One microgram of plasmid DNA was used to transform E. coli with heat shock at 42°C for 30 
sec, bacteria were grown overnight at 37°C in LB medium composed of 5 g bacto-yeast 
extract, 10 g bacto-tryptone, 10 g NaCl, 1 ml ampiciline 1 mg/ml and 1 l water. The plasmid 
DNA was extracted and purified with QIAfilterPlasmid Maxi Kit (QIAGEN, Duesseldorf, 











Fig.17 Transfection scheme 
 
For each MA-NB cell lines, Phoenix packaging cells were seeded 2.8x105 cell/well in a six 
wells plate, the day after the cells were transfected with 5 µg plasmid DNA and 10 µl 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) in 1 ml of DMEM for 5 hours at 
37°C. After the incubation 1 ml DMEM with 20% FBS was added and the day after the 
medium was changed. 1ml of medium contained retroviral ector particles, produced in the 
Phoenix packaging cell line, were filtered and introduced into MA-NB cell lines with 
Polybrene 8 µg/ml (Millipore, Billerica, MA) and 5 ml fresh medium. 2x105 cells of IMR-5, 
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cell line were seeded. After transduction, the NB cell lines were selected with 1 mg/ml G418 
(GIBCO-Invitrogen, Carlsbad, CA) for 14 days, then stable transfectants Luciferase 
expression in 105 live intact cells was examined using Luciferase Assay Reagent (Promega, 
Madison, WI) and measured with a spectral scanning multimodal plate reader (Varioskan 
Flash, Thermo Scientific, Whaltham, MA) in the 560-70 nm range of absorbance. Six 
different dilution (106, 105, 104, 103, 102, 10) of luciferase positive NB live intact cells were 
analysed on the LB 981 (Berthold Technologies) after added of 100 µl of D-Luciferin Steady-
Glo Luciferase Assay System (Promega, Madison, WI). 
 
2.5 Oligonucleotide-mediated gene modification in 
murine ES cells 
The pSUPER-MLH1 plasmid and the two single-stranded OligoDeoxyriboNucleotides 
(ssODNs) were transfected following the TransFast-mediated transfection method [174]. 
7x105 ES cells were seeded onto a gelatin-coated 6-well in BRL-conditioned medium the day 
before transfection. For one well, 3 µg of pSUPER-MLH1 and 27 µl of TransFast transfection 
agent (Promega, Madison, WI) were diluted in 1.4 ml serum-free medium and incubated 15 
min at room temperature. After 75 min of exposure to the transfection mixture at 37°C, 4ml of 
BRL-conditioned medium with serum was added to the cells. The cells were incubated over 
night and then each well was reseeded onto a new gelatin-coated well in 3 ml BRL-
conditioned medium with 44.5 µl puromycin (1.8 µg/ml, SIGMA-ALDRICH, Milwakee, 
WI). After 48 hours of puromycin selection, cells were washed twice with PBS and one well 
was used for tranfection with sense ssODN (RD151, 1 µg/µl, SIGMA-ALDRICH, Milwakee, 
WI) and one with antisense ssODN (RD152, 1ug/µl, SIGMA-ALDRICH, Milwakee, WI). For 
one well, 3 µg of ssODN and 27 µl of TransFast transfection agent (Promega, Madison, WI) 
were diluted in 1.4 ml serum-free medium and incubated 15 min at room temperature. After 
60 min of exposure to the transfection mixture at 37°C, 4 ml of BRL-conditioned medium 
with serum was added to the cells. ES cells were expanded and plated in pools of 5000 cells 
for well onto four 96-well feeder plates containing irradiated mouse embryonic fibroblasts 
(MEFs). In 3 subsequent screening rounds, cells were s eded onto 96-well MEF feeder plates 
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cells were seeded in 10 cm gelatin-coated dishes for col ny picking. 300 colonies were picked 
and the best was reseeded in 10 cm gelatin-coated dish to be sure that a positive single-cell 
clone is truly clonal [176]. 
After establishment of a pure clonal cell line, I verify the presence of the target mutation 
by sequencing. The total RNA was isolated from 3x105 positive clonal cells using RNAzol B 
(IsoTex Diagnostics, Inc): add 250 µl RNA-Bee to the cell pellet; pipet the lysate several 
time; add 50 µl chloroform; shake vigorously and incubate on ice for 5 min. Centrifuge at 
12000 g for 15 min at 4°C; transfer the aqueous phase to a clean tube; add 125 µl isopropanol 
and incubate at room temperature for 15 min; centrifuge at 12000 g for 10 min at 4°C; remove 
the supernatant  and wash the pellet twice with 250 µl 75% ethanol; centrifuge at 7500 g for 5 
min at 4°C. Briefly air-dry the RNA pellet and dissolve RNA in 15 µl water. Total RNA was 
run in a 2% agarose gel and it was read at Nanodrop ND-1000 (NanoDrop Technologies, 
Wilmingon, DE). 1 µg of total RNA was reverse transcribed in cDNA using SuperscriptII RT 
enzyme (Invitrogen): add at the sample 1 µl dNTP 10 mM, 0,25 µl random examers (1 µg\ µl) 
and 11 µl of water, incubate the mix for 5 min at 65°C and for 1 min in ice. Add 4 µl 5x 
Buffer, 2 µl 0.1M DTT, 1 µl RNase OUT to the sample, incubate at 25°C for 2 min, add 1 µl 
of Superscript II RT Enzyme (200U), incubate at 25°C for 10 min, incubate at 50°C for 40 
min and at 70°C for 15 min.  
200-400 ng of cDNA were amplified in a PCR reaction with primers spanning the mutation. 
The reaction contained 2 µl Buffer II 10x (Applied Biosystem, Roche), 0,5 µl dNTPs 10 mM, 
0,5 µl Taq DNA polymerase 1U (Euroclone), 0,8 µl forward primer 100 µM 
(ACCCCTTTGGCTCATTCTCT), 0,8 µl reverse primer 100 µM 
(CCTGAAGGATGACCGGATTA), 13,4 µl of water. I used PTC-200 Peltier Thermal Cycler 
(MJ Research) and PCR reaction conditions were 3 min at 94°C, for 40 cycles: 30 sec at 
94°C, 30 sec at 60°C, 30 sec at 72°C and a final step of 2 min at 72°C.  I analysed the PCR 
product on a 1,6% agarose gel in TAE 2.5x buffer. 
I cut the 479 bp fragment from the gel under UV Transilluminator (UVP,Inc) and I used 
QIAquick Gel Extraction Kit (QIAGEN, Duesseldorf, Germany) to extract DNA: weigh gel 
slice, add 600 µl of Buffer QG; incubate at 50°C for 10 min with 14000 rpm shaking in 
Thermomixercompact (Eppendorf); add 200 µl isopropan l; apply the sample to the 
QIAquick column; centrifuge 1500 rpm for 2 min; discard flow-through; add 750 µl of Buffer 
PE; centrifuge 13000 rpm for 1 min; discard flow-through; centrifuge 13000 rpm for 1 min; 
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quantified using NanoDrop ND-1000 (NanoDrop Technologies, Wilmingon, DE).                          
I cloned the fragment in pGEM®-T Easy vector (Promega, A1360; Madison,WI): prepare one 
Standard Reaction with 5 µl 2x Rapid Ligation Buffer; 1 µl pGEM®-T Easy vector; 1 µl T4 
DNA Ligase (3 Weiss units/µl); 3 µl PCR product (25 ng) and a Background Control 
Reaction with 5 µl 2x Rapid Ligation Buffer; 1 µl pGEM®-T Easy vector; 1 µl T4 DNA 
Ligase (3 Weiss units/µl); 3 µl water. Incubate both reactions for 60 min at room temperature. 
The ligated DNA was subcloning in DH5α™ Competent Cells (Invitrogen): thaw on ice 
DH5™ cells; add 2 µl DNA or 2 µl Background Control; incubate on ice for 30 min; heat 
shock cells for 20 sec in a 42°C water bath; incubate on ice for 2 min; add 950 µl pre-warmed 
LB medium; incubate at 37°C for 60 min at 225 rpm; spread 50 µl from each transformation 
on pre-warmed selective plates (1x); centrifuge eppendorf at 8000 rpm for 1 min; under 
bunsen burner remove 870 µl medium; resuspend and spread the cell suspension on pre-
warmed selective plates (10x);  incubate plates for 16 hours at 37°C. Count colonies on 
transformed plates; pick 23 colonies under bunsen bur er; seed each colony in 2 ml of LB 
medium with 2 µl ampicillin; incubate tubes for 16 hours at 37°C and 150 rpm. Isolate the 
transformed DNAfrom minicolture with miniprep protocol: centrifuge 2 min at 8000 rpm; 
remove surnatant; add 100 µl solution I (5 ml 1M TrisHCl pH8.0, 9 ml 20% glucose, 4 ml 6.5 
M EDTA, 182 ml demi water) and vortex; incubate for 5 min at room temperature; add 180 µl 
fresh solution II (0,4 ml 5N NaOH, 0,5 ml 20% SDS, 9,1 ml demi water) and vortex; incubate 
on ice for 5 min; add 150 µl cold solution III (60 ml 5M KAc, 11,5 ml acetic acid, 28,5 ml 
demi water) and vortex; incubate on ice for 5 min; centrifuge at 4°C at 14000 rpm  for 5 min. 
Transfer supernatant in eppendorf containing 800 µl 100% ethanol; centrifuge at 14000 rpm  
for 15 min; remove supernatant; add 200 µl 70% ethanol; centrifuge at 14000 NanoDrop 
Technologies, Wilmingon, DE).  0,2 µl miniprep DNA samples were digested rpm  for 2 min; 
remove supernatant; add 25 µl T10E1 and RNase (mix 5 ml T10E1 and 3 µl RNase). The 23 
miniprep DNA were quantified using NanoDrop ND-1000 (with 1 µl Eco RI restriction 
enzyme in presence of 1 µl buffer H and water. To a fin l volume of 20 µl. The digestion 
product was analysed on a 0,6% agarose gel in TAE 2.5x buffer. 
The positive samples presented a 500 bp fragment and a 3000 bp fragment (empty pGEM®-T 
vector).  16 clones were processed with BigDye®Terminator v3.1 Cycle Sequencing Kit 
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2.6 In vitro treatment 
PNAs-NLS was added at concentrations of 2.5, 5, 10 µM on Kelly and SK-N-BE(2)c 
and at the optimal concentration of 10 µM on IMR-32, IMR-5, NHO2A [229]. To evaluate 
the specificity of the effect of PNAs-NLS on MYCN, IMR-32, IMR-5, SK-N-BE(2)c, Kelly 
and NHO2A were treated at 10 µM with PNAmt-NLS. Cells were harvested and analysed at 
24, 48 and 72 hours after treatment. Cell count wasdetermined by the trypan blue dye 
exclusion method and cell viability was determined with ATPlite proliferation assay (see 
section 3.3). For each well, PNAs or PNAmt were diluted in serum-free medium and after 6 
hours serum was added to the cells to avoid that the PNA molecules didn’t precipitate in 
presence of serum (observed in laboratory experiments). Each experiment was repeated on at 
least three times. 
To analyse the possible synergy of the PNAs-NLS with the conventional 
chemotherapeutic drugs used in clinical protocol against MYCN amplified neuroblastoma, the 
cell lines were treated at different concentration with Carboplatin (CBDCA), Cysplatin 
(CDDP), Vincristine (VCR) and Etoposide (VP-16) and analysed after 72 hours with ATPlite 
kit (see section 3.3). The concentration range used is shown in the table below (Tab.2). At the 
beginning we tested the concentration used in Fulda S., EJC 1995 and after several 
experiments we obtained our concentration ranges [232]. Each experiment was repeated on at 
least four times.   
 
        Log[drug] 
Cell lines 
CBDCA (µM) CDDP (µM) VCR (nM) VP-16 (µM) 
IMR-32 -1.22/2.78 -0.35/2.65 -3/1 -1.16/2.85 
IMR-5 -0.22/2.78 -2.35/2.65 -1/3 -5.15/1.85 
SK-N-BE(2)c 0.78/3 -0.35/1.65 -1/3 -1.15/3.1 
Kelly -2.34/1.77 -3/1.65 -4/0 -0.34/1.85 
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2.7 TH-MYCN mice colony 
All the experiments involving animals were reviewed and approved by the Bioethical 
Committee of Bologna University, Italy and by Italian Ministry of Health. Animals were kept 
under pathogen free conditions, with ad libitum access to food. TH-MYCN murine model was 
generated and kindly provided from W. A. Weiss, Department of Neurology, University of 
California, San Francisco [88]. To obtain a TH-MYCN mice colony we ordered also 8 
129X1/Svj mice females of 8 week old to The Jackson Laboratory (Bar Harbor, ME). The 
strain 129 is a good breeder, at the beginning the mating system was between wild-type 
females and 3 hemizygous TH-MYCN males. Genomic DNA was isolated from mouse-tail 
tips harvested when animals were 17 days old. The lysis buffer used is constituted of Tris 1 M 
pH8.5, EDTA 0.5 M pH8, NaCl 5 M, SDS 10% and water. Each tail tip was incubated over-
night in agitation in 500 µl lysis buffer and 2.25 µl proteinase K(Sigma). The suspension was 
put in 500 µl iso-propanol, gently mixed and DNA tail was picked and put in 100 µl Elution 
Buffer over-night at 37°C. Each DNA sample was quantified twice with the NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmingon, DE). The genotypes of 
MYCN transgenic mice were determined by qualitative PCR analysis using primers RBBI2 
(411) s (TGGAAAGCTTCTTATTGGTAGAAACAA), MYCN (26) as 
(AGGGATCCTTTCCGCCCCGTTCGTTTTAA) from http://mouse.ncifcrf.gov  and as 
housekeeping mACTB (911) s (GCTCCTCCTGAGCGCAAG), mACTB (1106) as 
(ATGGAGGGGCCGGACTC). PCR reaction contained 100 ng gDNA, Buffer II 10x 
(Applied Biosystem, Roche), 0.8 mM dNTPs, 2 mM MgCl2, 0.2 µM primer reverse and 
forward, 1U Taq DNA polymerase (Euroclone). We used PTC-225 Peltier Thermal Cycler 
(MJ Research) and PCR reaction conditions were 1 min at 95°C, for 40 cycles: 30 sec at 
94°C, 30 sec at 68°C, 1 min at 72°C and a final step of 7 min at 72°C.  We analysed the PCR 
product on a 1% Agarose gel with EtBr in TBE 0.5x. 
Later, we started mate between hemizygous mice and we obtained also homozygous 
mice for the human MYCN transgene. Homozygous mice were identified analysing tail DNA 
not by southern blotting [88] but by real-time quantitative PCR with a new set of primers 
designed on the sequencing of an hemizygous PCR product. The primer sequences are: 
RBBI2 (533) s (CCTCTGCTAACCATGTTCA), MYCN (-128) as 
(ACAGCTCAAACACAGACAGAT) and as housekeeping mPOLR2DI1 (1151) s 
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qPCR analysis was performed to quantified human MYCN amplification using 
LightCycler  480 Roche, according to the manufacture’s instruction and SYBR Green I 
Master (Roche Applied Science, Mannheim, Germany). The real-time quantitative PCR was 
performed adding to 10 ng cDNA (4 µl final volume), 10 µl Fast Star SYBRGreen MasterMix 
2x (Roche), 0.6 µl primers forward and reverse 10nM and water to final reaction volume of 
20 µl. PCR reaction conditions were 2 min at 50°C, 10 min at 95°C, for 50 cycles: 15 sec at 
95°C, 60 sec at 60°C. The dosage of transgene in the samples was determined using the ∆∆Ct 
method, a comparative technique in which target gene dosage is normalized to the 
housekeeping gene control and relative to a calibrator (parents of each progenies and 476 
hemizygous mouse).  
In vivo experiments were performed using 22 hemizygous mice for microPET 
experiment, 40 homozygous mice to create the micro PET tumour progression curve and 9 
homozygous mice to treatment.   
 
2.8 Establishment orthotopic xenograft models 
All experiments involving animals were reviewed and approved by the Bioethical 
Committee of Bologna University, Italy and by Italian Ministry of Health. Animals were kept 
under pathogen free conditions, with ad libitum access to food. After an ectotopic xenograft 
model experiment, orthotopic xenograft models were established by injection of 2x106 IMR-
32, SK-N-BE(2)c and IMR-5 cells in 20 µl NaCl solution. Four-week-old NOD-SCID mice 
(Charles River Laboratories, France) were anesthetized with 0.3 mg/kg body weight Zoletil 
100 and Atropine Sulphate 1 mg/ml, subjected to laparotomy, and injected with 
neuroblastoma cells into the right adrenal gland.  We confirmed the tumor presence with 
palpation, a microPET analysis and tumor histology. Luminescent p53 mutated orthotopic 
xenograft model was established by injection of 2x106  Luciferase-positive SK-N-BE(2)c cells 
while Luminescent p53 wild type orthotopic xenograft models were established by injection 
of 2x106 Luciferase-positive cell lines (IMR-32, Kelly, IMR-5) in 20 µl NaCl solution. Four-
week-old NOD-SCID mice (Charles River Laboratories, France) were anesthetized with 0.3 
mg/kg body weight Zoletil 100 and Atropine Sulphate 1 mg/ml, subjected to laparotomy, and 
injected with neuroblastoma cells into the right adrenal gland. No mice died as a result of this 
treatment. General physical status of the animals were recorded daily, and mice were killed by 
cervical dislocation after being anesthetized with 0.3 mg/kg body weight Zoletil 100 (Virbac 
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confirmed in each models with Bioluminescence Imaging analysis and histology. All in vivo 
experiments were performed using 4 mice each cell line to set the model, 10 mice each 
luciferase-positive cell line to perform the luminesc nt progression curve, 8 mice were treated 
with chemotherapeutic compounds.   
 
2.9 Molecular imaging 
We used two different Imaging methods: microPET andBioluminescence Imaging. All 
experiments involving animals were reviewed and approved by the Bioethical Committee of 
Bologna University, Italy and by Italian Ministry of Health. 
Thanks to small animal micro PET imaging (Nuclear Medicine, S.Orsola-Malpighi 
Hospital, University of Bologna, Italy), we studied 37 hemizygous mice and 60 homozygous 
mice [233]. The animals’ weight ranged from 14 to 26g.  
Thirtyseven hemizygous animals underwent several smll animal PET scans with 18F-FDG, 
twice in a week, and 18F-DOPA every week for two months from 20 to 50 days fter birth. 
Sixty homozygous mice underwent several micro PET scan  with 18F-FDG, every three days 
for two months from 27th days of live until detection of positivity and from this initial point 
every week. We used hemizygous mice to compare 18F-FDG and 18F-DOPA, as radiolabelled 
compounds and evaluate their physiological and tumor uptake and a homozygous mice were 
analyzed to define a temporal window in which to detect the beginning of the tumor and to 
follow its progression. 
The whole diagnostic procedure was carried out under a warm light to maintain the body 
temperature, especially during anaesthesia. The animal was anaesthetised with gas anaesthesia 
(Sevofluorane 3–5% and oxygen 1 l/min) and it was injected with 30 MBq of 18F-FDG in a 
volume of 0.15 ml, or 30MBq of 18F-DOPA in a volume of 0.25 ml, via tail vein with an 
insulin syringe. The animal was subsequently allowed to wake up for the uptake period (60 
min), during which it was allowed to move freely. The residual dose was measured to verify 
the effective dose injected. Finally, a second anaesthesia was applied in the same way to 
perform the scan. Each anaesthetised animal was placed on the scanner bed in prone position. 
Images were acquired with a small animal PET tomograph (GE, eXplore Vista DR) for a total 
acquisition time of 20 min. As the axial field of view was 4 cm, one bed position was 
sufficient to cover the whole body. Once the scan hd been completed, the gas anaesthesia 
was interrupted and the animal was placed in a warm recovery box until complete recovery.  
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2D and read in three planes (axial, sagittal and coronal); the scan was considered positive if 
areas of increased uptake were present at sites consiste t with the site of insurgence of the 
tumor. Necrosis was diagnosed when a cold central are  ppeared within the neoplastic mass. 
Semi-quantitative analysis was carried out for each identified tumour obtained from 18F-FDG 
scan using the Target-to-Background-Ratio (TBR). TBR was calculated with the following 
formula (Max Count in the Target ROI) ⁄ (Mean Count in the Background ROI). The target 
region of interest (ROI) was placed on the most active area of the neoplastic mass (excluding 
necrotic areas) and as background ROI we chose a region of the skin surrounding the tumor. 
Mean TBR was calculated for each scan. Normal subcutaneous tissues had a TBR of 0.3. We 
also calculated tracer uptake in tumors with Standardized Uptake Value (SUV), correcting the 
value with the mean tumor volume that correspond at each positive micro PET point. The 
SUV is the ratio of the activity concentration measured in the microPET image and the 
injected dose divided by the animal’s weight. All animals were sacrificed and histology was 
performed to verify PET results. 
 
Thanks to Bioluminescence Imaging, we analysed luminescent orthotopic xenograft 
mice models. We performed an in vivo experiment to understand the kinetic and the body 
distribution of the substrate. A IMR-5 luciferase positive mouse received an intra peritoneal 
injection of 150 mg/kg D-luciferin (Gold Biotechnology, St.Louis, MO, USA), it was placed 
in the lith-tight chamber OD, a cooled CCD camera system LB981 (Berthold technologies, 
Wildbad, Germany) (Pharmaceutical Sciences, S.Orsola-Malpighi Hospital, University of 
Bologna, Italy) under Isoflurane anaesthesia (Isofluorane 3% and oxygen 1 l/min). 
Luminescent signals were acquired each 30 sec for 1min for a total of 15 min. After this 
previous study, all mice received an intra peritoneal injection of 150 mg/kg D-Luciferin and 
placed in the lith-tight chamber OD, under Isoflurane anaesthesia. Pictures and luminescent 
images were acquired 8 min after D-luciferin injection in prone position for 3 min. The 
Winlight software version 2.9 of the low-light imager system LB981 (Berthold technologies, 
Wildbad, Germany) was used to analyze the BLI data. The luminescent signals were 
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2.10 In vivo treatment 
PNAsense was administered by intra peritoneal injection at a dose of 50 mg/kg in 
microPET positive homozygous TH-MYCN mice of 35 days. Two schedules were performed: 
two mice were treated each two days for a total time of 20 days and one mouse was treated 
each days for a total time of 20 days. A group of 6 control animals were simultaneously 
treated with NaCl solution. All animals were monitored during the study, the weight and 
general behavior of each mouse were misured. Mice wer  sacrified at first sign of distress. 
An initial dose-response study was performed using the p53 mutant model (SK-N-BE2c 
Luc mice) and a p53 wt (Kelly Luc mice) orthotopic xenograft model with two chemo 
therapeutical drugs, vincristine (0.06 mg/kg) and etoposide (14 mg/kg). Two animals for each 
model were treated and a group of 4 control animals were simultaneously treated with NaCl 
solution. These concentrations were obtained from the used concentrations in the treatment of 
high risk neuroblastoma patients.  
2.11 Histology and immunohistochemistry 
Each NB sample was divided into two parts. A NB piece was frozen in liquid nitrogen 
and it was kept at -80°C for molecular analysis and other piece was fixed in formalin for 
histological analysis.  
To assess the potential toxic effect of PNAwt, histological analysis was performed in all 
major organs in two wild-type 129X1/SvJ mice subjected to the same treatment schedule with 
PNAwt or saline. Together with Dr. Korinne Di Leo evaluated different organs: heart, lungs, 
liver, pancreas, parotid glands, esophagus, intesties, kidneys, adrenal glands, uterus, ovary, 
spleen, thymus, brain, bone marrow and peripheral blood.  
Murine tissues were fixed in 4% formalin, dehydrated, mbedded in paraffin, cut into 4 
µm sections and stained with hematoxylin an eosin (H&E) methods. Bone marrow and 
peripheral blood were evalueted with May-Grunwald-Giemsa staining. For hematoxylin-eosin 
staining, tissue sections were subjected to subsequent incubations in toluene, 100% ethanol, 
95% ethanol, 70% ethanol, distilled water, hematoxylin, distilled water, eosin, distilled water, 
70% ethanol, 95% ethanol, 100% ethanol and toluene. Aft r coverslip application, slides were 
observed by light microscopy.  For May-Grunwald-Giemsa staining, the slides with blood 
smears were subjected to subsequent incubation with May-Grunwald for 3 min, washing in 
water, incubation with Giemsa for 7 min, washing in distilled water. After coverslip 
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NB tissue sections were processed for immunohistochemistry. Sections were subjected to 
subsequent incubations in xilene, 100% ethanol, methanol and 0,3% hydrogen peroxide, 96% 
ethanol, 70% ethanol, distilled water and then incubation in citrate buffer in pressure cooker. 
The sections were washed with 1x PBS, incubated with goat serum for 15 min at room 
temperature, washed with 1x PBS and incubated with 1:75 anti-N-Myc primary antibody 
(Oncogene) over night. The day after the slides were washed in 1x PBS and they were 
incubated with anti-mouse secondary antibody (DAKO, Evision) for 20 min. After wash in 
1xPBS, they were developed with a 5% Di-Amino-Benzidine chromogen in TAI Buffer pH 
7.6 with 3% hydrogen peroxide. After wash in 1x PBS slides were subjected to subsequent 
incubations in distilled water, hematoxylin, distilled water, 70% ethanol, 95% ethanol, 100% 
ethanol and toluene. After coverslip application, slides were observed by light microscopy.  
 
2.12 Fluorescence In Situ Hibridization (FISH) 
FISH analysis was performed on fixed NB cells and o paraffin embedded tissue to 
confirm MYCN amplification. The tissue slides were t ated with Paraffin Pre Treatment Kit 
from Abbott Molecular Inc (Des Plaines IL 60018 USA) and FISH analysis was performed 
according to the protocols recommended by the manufact rer (Vysis Inc., Downers Grove, IL, 
USA). Specific locus probe for MYCN (LSI-N-MYC(2p24), Vysis) and centromeric probe 
for chromosome 2 (CEP2(2p11.1-q11.1), Vysis) were us d. Hybridization signals were 
analysed on a Olympus BX51 microscope coupled to a Cytovision Ultra system (Applied 
Imaging, Sunderland, UK).  
 
2.13 DNA isolation and gene amplification analysis 
Genomic DNA was isolated from NB cell lines and from frozen murine tissues using 
NucleoSpin Tissue (Macherey-Nagel). According to the User Manual Genomic DNA from 
Tissue: collect ten millions cultured cells, resuspend in 200 µl lysis buffer T1, add 25 µl 
proteinase K solution and 200 µl Buffer B3, incubate the sample 15 min at 70°C. Collect 25 
mg murine tissue (from tumour, liver and other organs), treated in a mechanical homogenizer, 
add 200 µl Buffer T1 and 25 µl proteinase K solution, vortex briefly the sample, incubate at 
56°C over-night. Add 210 µl ethanol absolute to both sample types, place each sample into a 
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with 500 µl Buffer BW, 1 min at 11000 x g, add 600 µl Buffer B5, 1 min at 11000 x g, 1 min 
at 11000 x g. Place the NucleoSpin Tissue Columnin a new microcentrifuge tube, add 100
µl prewarmed Elution Buffer (70°C), 1 min at 11000 x g. Each DNA sample was quantified 
twice with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmingon, 
DE). 
qPCR analysis was performed to confirm MYCN amplificat on using LightCycler 480 
Roche, according to the manufacture’s instruction and SYBR Green I Master (Roche Applied 
Science, Mannheim, Germany). The real-time quantitative PCR was performed added to 10 
ng gDNA (4 µl final volume), 10 µl Fast Star SYBRGreen MasterMix 2x (Roche), 0.6 µl 
primers forward and reverse 10 nM and water to final re ction volume of 20 µl. PCR reaction 
conditions were 2 min at 50°C, 10 min at 95°C, 15 sec at 95°C, 60 sec at 60°C for 50 cycles. 
The dosage of target gene in the samples was determined using the ∆∆Ct method, a 
comparative technique in which target gene dosage is normalized to the actin control and 
relative to a calibrator.  
The primer sequences are: MYCN (49) s (CCAGACCTCGAGTTTGACTC), MYCN 
(161) as (TCAAACTTCTTCCAGATGTCC) and as housekeeping β-actin (991) s 
(GCTCCTCCTGAGCGCAAG), β-actin (1106) as (ATGGAGGGGCCGGACTC) for MYCN 
amplification analysis.  
Genomic DNA was isolated from mES cells in 96-wells p ate using a proper lysis buffer 
containing 100 mM Tris pH 8.0, 5 mM EDTA, 200 mM NaCl, 0.2% SDS and fresh 200 
µg/ml Proteinase K. In each well add 50 µl lysis buffer, incubate the plate for 2 hours at 55°C, 
add 100 µl ethanol absolute, seal the plate and carefully invert it five times, 30 min at 3000 g 
at 4°C, remove supernatant, add 100 µl 70% ethanol, 15 min at 3000 g at 4°C, remove 
supernatant and add 60 µl Elution Buffer, incubate at 55°C over-night. qPCR analysis was 
performed to quantify the mutation title of each sample using LightCycler 480 Roche, 
according to the manufacture’s instruction and SYBR Green I Master (Roche Applied 
Science, Mannheim, Germany). The real-time quantitative PCR was performed added to 2 µl 
gDNA, 1.6 µl Fast Star SYBRGreen MasterMix 2x (Roche), 0.125 µl primers forward and 
reverse 10 pM and water to final reaction volume of 10 µl. PCR reaction conditions were 2 
min at 50°C, 10 min at 95°C, for 50 cycles: 15 sec at 95°C, 60 sec at 66°C. The dosage of 
mutant allele was determined using the ∆Ct method, a comparative technique in which mutant 
allele dosage is normalized to the wild type allele in ach sample.  
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as (GTCTGGGTTCTTGCAGATCAAC) for wild-type mMYCN sequence, RD155 s 
(CTCTCCACGGGAAGGAAGCACTC) and RD156 as 
(GTCTGGGTTCTTGCAGATCAAG) for mutant mMYCN.  
 
2.14 RNA isolation and gene expression analysis 
Total RNA was extracted from 2x106 NB cell lines and from 30 mg of frozen tissues 
according RNAspin Mini RNA Isolation Kit (GE Healthcare, UK): after homogenization, add 
350 µl Buffer RA1 and 3.5 µl β-mercapto-ethanol to the samples. To clear the lysate filter it 
with a RNAspin Mini Filter unit. Centrifuge 1 min at 11000 x g, add 350 µl 70% ethanol, mix 
the samples and load them into a RNAspin Mini column. After 30 sec at 8000 x g, add 350 µl 
Membrane Desalting Buffer, centrifuge for 1 min at 11000 x g to dry the membrane. 
Centrifuge for 1 min at 11000 x g, digest DNA with 95 µl of DNase reaction mixture, 
incubate for 15 min at room temperature. Wash the membrane with 200 µl Buffer RA2, 
centrifuge 11000 x g for 1min, add 600 µl Buffer RA3, centrifuge 11000 x g for 1 min, add 
250 µl Buffer RA3, centrifuge 11000 x g for 2 min. Elute the RNA in 40 µl H2O RNase–free. 
Each RNA sample was quantified twice with the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmingon, DE). The 2 µg RNA (final volume of 10 µl) was 
reverse transcribed using Superscript II RNAseH (Invitrogen): add 1 µl dNTP 10 mM and 1 
µl oligo dT to 10 µl of sample, incubate the mix for 5 min at 65°C and for 1 min in ice. Add 4 
µl Buffer 5x, 2 µl DTT 0.1M, 1 µl RNase OUT to the sample, incubate at 42°C for 2 min, add 
1 µl of Superscript II (50U), incubate at 42°C for 50 min and at 70°C for 15 min. Quantitative 
PCR analysis was performed to confirm MYCN over expr ssion and to analyse the efficacy of 
the PNA treatments. We used LightCycler 480 Roche, according to the manufacture’s 
instruction and SYBR Green I Master (Roche Applied Science, Mannheim, Germany). The 
real-time quantitative PCR was performed added to 10 ng cDNA (4 µl final volume), 10 µl 
Fast Star SYBRGreen MasterMix 2x (Roche), 0.6 µl prime s forward and reverse 10 nM and 
water to final reaction volume of 20 µl. PCR reaction conditions were 2 min at 50°C, 10 min 
at 95°C, for 50 cycles: 15 sec at 95°C, 60 sec at 60°C. Each sample was amplified in 
triplicate. ∆∆Ct calculations were used to determine the level of expression of target genes 
relative to reference control and to a calibrator (untreated samples or normal tissue).  
The primer sequences for analyse MYCN over expression in NB tumors, NB cell lines 
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Name Sequence Type 
MYCN (741) s CGACCACAAGGCCCTCAGT Target gene 
MYCN (841) as TGACCACGTCGATTTCTTCCT Target gene 
β-actin (700) s TCCTCCCTGGAGAAGAGCTACGAG Reference gene 
β-actin (1018) as ACACGGAGTACTTGCGCTCAGG Reference gene 
MYC (794) s GCGACTCTGAGGAGGAACAAGA Target gene 
MYC (929) as GAGCCTGCCTCTTTTCCACA Target gene 
BIRC4 (839) s ACAAGGAGCAGCTTGCAAGA Reference gene 
BIRC4 (963) as AGCATGTTGTTCCCAAGGGT Reference gene 
 
 
2.15 Protein extraction and western blot analysis 
The N-myc protein was assessed in total protein extracts. The total proteins were 
extracted resuspending the pellet of cells or homogenized tissues in a lysing solution 
consisting 0.1 M KH2PO4 pH 7.5, Igepal 1%, 0.1 mM β-glicerolfosphate and a Complete 
Protease Inhibitors (Roche). After 10 min of incubation on ice, the sample was centrifuged at 
15000 x g for 3 min at 4°C and the supernatant was collected containing total cellular 
proteins. 
  Protein were quantified with Lowry method [234] and the standard curve was 
constructed using known amounts of BSA protein (Bovine Serum albumin), by reading in a 
spectrophotometer at 660 nm (Beckman). 
Proteins were separated by one-dimensional gel electrophoresis in denaturing conditions 
(SDS-PAGE: Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophore). The samples, 
containing 100 micrograms of proteins were solubilized by incubation at 95°C for 5 min after 
the addition of 2X Laemmli sample buffer (125 mM Tris pH 7, 4% SDS, 20% glycerol, 10% 
β-mercaptoethanol and bromophenol blue 0.004%) and water to a volume of about 20 ml. 
Following the preparation of Separating gel 7-10% (7-10% acrylamide, 375 mM Tris pH 8.8, 
0.1% SDS, 0.1% APS, TEMED 0.1%) and 4% stacking gel (4% acrylamide, 125 mM Tris 
pH 6.8, 0.1% SDS, 0.1% APS, TEMED 0.1%), the samples were loaded in gel 
electrophoresis and run at 160 V for about 60-90 min in electrophoresis buffer (125 mM Tris, 










   Proteins were separated by SDS-PAGE and they were transferred to PVDF membrane 
(polyvinylidene fluoride, Hybond-P, Amersham Biosciences) by western blot using the Bio-
Rad wet system (Mini Trans-Blot Cell). The membrane was activated in methanol for 10 sec 
and then re-balanced in water for 5 min. Sponges and filters, before use, were soaked in 
transfer buffer (25 mM Tris, 192 mM glycine, methanol 10%), and then were assembled filter 
sponge-gel-membrane-filter-sponge and the transfer is was performed in transfer buffer at 250 
mA for 2 hours. The membrane was subjected to succesive incubation of 1 hour at room 
temperature with blocking solution (PBS, Tween 0.2% and 5% milk), with the primary 
antibody: mouse monoclonal N-myc IgG (NCM II 100, Calbiochem) or mouse monoclonal ß-
actin (Calbiochem) and, after 3 washes in PBS and Tween 0.2%, with corresponding 
secondary antibody Sheep anti-mouse IgG-HRP (horseradish peroxidase)  (Amersham 
Biosciences). All antibodies were diluted in PBS, Tween 0.2% and 3.5% BSA. The 
membrane was washed 3 times in PBS and 0.2% Tween for 5 min and was incubated for 1-2 
min in the dark with the ECL detection solution (Amersham Biosciences). The survey was 
carried out to ChemiDoc (Biorad), using the program QuantityOne.  
 
2.16 Mutant MYCN mice 
 The pure clone obtained with oligotargeting tecnique was injected in blastocysts to 
obtain a mutant mouse with the single point mutation in murine MYCN gene.    
Blastocysts, a pre-implantation embryos, are isolated from 24 wild type donor females 3.5 
days after mating and microinjected with 12 genetically modified mouse embryonic stem 
cells. 15-12 injected blastocysts are transplanted to the uterus of pseudopregnant recipient 
females that have been mated with sterile males. Offspring developed from successfully 
injected blastocysts will be a mixture of wild type c lls and genetically modified cells, so 
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agouti (brownish-grey) coat colour and the blastocysts come from a strain with black coat 
colour (Black6). Some of the offspring born will bewild type mice (black) and others will be 
chimeras (patchy black/brown), the latter will be mated to investigate if the genetic 
modification can be inherited, i.e. transmitted through the germ line. 
The chimeras are mated to 129/ola wild type mice and if the germ cells of the chimera 
originate from the genetically modified cells, the modification (-) can be inherited by the 
offspring. The wild type allele is denoted +. The chimeras are mated to bejge wild type mice, 
and the offspring can have either black or bejge coat lour.  All bejge pups originate from 
germ cells in the chimera that are of 129 origin will be genotyping for the mutation.  When 
the heterozygous (+/-) mice are mated, 25% of the offspring in the F2 generation will be 
homozygous for the mutation and we will have the homozigous mutation on mouse MYCN 
gene. 
 
2.17 Statistical analysis 
Both in vitro and in vivo data were presented as mean  Standard Error Mean (SEM). In
vitro data were obtained from at least three independent experiments. For the Xenograft 
murine models the bioluminescence intensity relative o the tumour progression was reported 
as mean  SEM considering the photon flux (ph/s) as the sum of prone signals for each 
mouse after background subtraction. The BLI curves for each xenograft model were 














3.1 MYCN-amplified neuroblastoma transgenic 
murine model  
3.1.1 TH-MYCN transgenic mice  
For the realization of the colony of TH-MYCN human Neuroblastoma mice we used 
the strain 129X1/SvJ, because the penetrance of the tumor increases, compared with the use of 
the C57BL/6J strain [88] [184]. Mice were mating between transgenic hemizygous 
129X1/SvJ-Tg (TH-MYCN) 41Waw male inbred mice and 129X1/SvJ female inbred mice. It 
was chosen to mate in harem transgenic male with wild-type females because it was shown 
that transmission of the transgene is better if it occurs through the male germ line, because of 
the imprinting (as also confirmed in the Mouse Repository site, Mouse Models for Human 
Cancers Consortium http://mouse.ncifcrf.gov ) [235] [236] Later we started mating between 
hemizygous mice to obtain homozigous mice. In four years the colony has reached the 
number of 719 animals, of which 60.4% were transgenic mice, shown by PCR analysis. We 










Genetic screening to distinguish homozygous and hemizygous mice was performed by 
quantitative Real-Time PCR analysis. I obtained genomic DNA of each mouse from a small 
piece of tail and in each sample it is measured the level of human MYCN cDNA 
amplification compared with brothers, parents and a hemizygous control mouse (476). Each 
progeny was obtained from mating an hemizygous male with an hemyzigous female mice. It 
followed that the RATIO (index which correlates theMYCN gene level with its housekeeping 
control gene level) of a homozygous sample is twice parents', brother's and hemizygous 
control level. In Figure 18, it is shown an example of genotyping analysis. 
 
Fig. 18. Genotyping of a family of TH-MYCN mice. The ratio s obtained between MYCN gene level and the 
housekeeping gene level of all the progeny comprise the parents, the analysis was normalized for MYCN level of 
an hemizigous control mouse (476 HEMI). The progeny included two homozygous specimens for that gene with 
a ratio around 2.0, one hemizygous mouse with a ratio of 1 and one wild-type specimen, that its ratio is closer to 
zero. Analyses carried out in duplicate. WT = wild-type mouse, HEMI  = hemizygous mouse for the human 
MYCN gene, HOMO  = homozygous mice for the human MYCN gene.  
 
After genotyping, hemizygous and homozygous mice were palpated weekly to 
identify the time and the mode of dissemination of the tumor mass, which usually appears in 
abdominal or thoracic position [88]. We observed a tumor in 96 hemizygous mice and in all 
95 homozygous mice: these data confirmed the literature data, in which hemizygous mice 
had a tumor incidence of 25-30%, in our case 28.3%. The observed latency was from 7 to 36 
weeks in hemizygous, while homozygous mice showed an early occurring around four weeks 














                                                                   
Fig. 19. Number of homozygous and hemizygous mice developed tumors. In the graph I show the total number 
of mice obtained (719) and in particular how many wild-type mice (285), hemizygous mice (339) and 
homozygous mice (95) there were. All homozygous mice developed tumors (100%) and only 28% of  
hemizygous mice developed tumors.   
 
The mass evolved rapidly in two-three weeks in homozyg us mice and in four-five 
weeks in hemizygous mice during which there was an increase in weight of 2-3 grams and 
mouse looked motionless, ataxic and curved. From the autopsy it was observed that at an 
early stage the tumor was present predominantly in the right part of the abdomen near kidney 
and in an advanced stage it was spread throughout te abdominal cavity incorporating 
kidneys, adrenal glands and a large part of the intstine. In advanced stage, cancer was 
composed of multiple hemorrhagic and necrosis masses and it was firmly attached to the 
spine. The adherence to the spine may suspect a bone marrow infiltration, which would 
explain the reduced mobility that we have seen, also observed in the literature [88]. 
Histological analysis of all tumors has confirmed that this is neuroblastoma (Fig. 20). 
 
Fig 20. H&E staining illustrates the presence of small round blue cells in the tissue and it confirms 










It was observed that the tumor progression in homozyg us mice reflected clinical setting. The 
short latency and the absolute incidence made this homozygous TH-MYCN mice model 
easier to monitor and useful to study possible pharmacological treatments. 
 
3.1.2 microPET analysis 
Four hemizygous mice were subjected periodically to Micro-PET analysis with 18F-
FDG from  day 20 after birth, every three days for 6 weeks. All mice were subjected to Micro-
PET analysis with also another radiotracer, 18F-DOPA, each week. The scans with 18F-DOPA 
are less than those with 18F-FDG, because the production of this radiotracer came only one 
time each week.  It was chosen to start the scans so early to detect the exact time of 
appearance of the tumor. In fact, even referring to literature on this transgenic model, many 
factors like the environment, the strain, create variability.  
In Micro-PET 18F-FDG images, the areas of high uptake of the radiotracer are located in the 
heart, which is an organ of high metabolic activity and bladder because here the tracer 
accumulates rapidly before elimination. These are the physiological areas of the 18F-FDG 
uptake. Since the early 18F-FDG scans, they highlighted elongated uptake areas in the 
abdomen and in a capturing area close to the dorsal spine, at the same level of the liver. From 
the Micro-PET images obtained with 18F-DOPA, the physiological areas of high uptake are 
spine, cerebral hemispheres, because of its uptake is related to the production of dopamine, 
and bladder. 18F-DOPA scans showed also two symmetrical absorber areas near kidneys, our 
interest area. Moreover it was often highlighted a orsal area in the same position also with 













Fig. 21. microPet analysis is made on the same mouse using two different radiotracers. 4.A 18F-FDG scan shows 
an abdominal uptake in addition to the areas of physiological uptake (heart and bladder) 4.B 18F-DOPA scan 
shows an abdominal uptake and the physiologic areas of uptake (SNC, SNP and bladder) 
 
Following these results mice were sacrificed to confirm if the abdominal areas uptake 
corresponded to a tumor. Necropsy has not identified th  presence of a tumor in these four 
animals.  
A second group of ten hemizygous mice were subjected periodically to Micro-PET 
analysis with 18F-FDG and 18F-DOPA from 40 days after birth for 4 weeks each four days. 
The scan starting date was determined by the fact that no hemizygous mice had developed 










Fig. 22. Tumor signal with both radiotracers in one mouse with advanced stage of Neuroblastoma. The figure 
shows sagital and coronal cuts. The images show abdominal areas more or less extensive composed of different 
uptake areas, moreover the level of uptake in some areas is comparable to the physiological uptake of heart and 
bladder.The tumor (white circle) is clearly more evid nt in 18F-FDG scan (left side), 18F-DOPA scan (right side) 
is less informing and the great urinary bladder radio ctivity saturates the image reducing the diagnostic power in 
the interested area (thick arrow).  
In this case the necropsy confirmed the presence of a tumor and histology showed that it was 
neuroblastoma. These were the first data that allowed correlate the Micro-PET analysis with 
histology, thanks to these data we decided to use the 18F-FDG radiotracer and not 18F-DOPA 
for the next studies.  
Twenty three hemizygous mice were subjected periodically to Micro-PET analysis 
with 18F-FDG from 40 days after birth for 6 weeks each four days. Only one mouse was 
positive at 64 days after birth, three were positives after the last scan, around 80-100 days 
after birth and other mice didn’t develop tumor. For money and time that each experiment 
required, next experiments were performed only on hmozygous mice because the onset is 
100% and the time of insurgence is more closer betwe n animals. 
Sixty homozygous mice were analyzed with 18F-FDG radiotracer. In the study twenty  
five homozygous mice have been included to define the temporal window for the appearance 
of the tumor and its progression. The examination was performed every three days starting 









mass (defined first positivity) and then every week (defined second, third, forth or fifth 
positivity, in accordance to mice’s life). Two examples of microPET analysis performed on 
two homozygous TH-MYCN mice are showed in figure 23 and 24. 
 
 
Fig. 23. MicroPET analysis of tumor progression and evolution on an homozygous mouse in three different 
sections. This animal survived until the third positivity. These scans show formation and evolution of the tumor 
mass on the right side of the animal. The color scale on the left of each image is the index of the prsence of 
radiotracer and it is directly proportional to the concentration of glucose in the tissues of the animl, except for 
the bladder where the radiopharmaceutical compound is accumulated to be excreted. Negative scan shows areas 
of high glucose metabolism (yellow signal) but, for their location there are no areas of overlap with a possible 
tumoral signal. In particular, in the sagittal section yellow areas show the heart and bladder, respectively, an 
organ with high metabolic activity and the site of c llection of the drug metabolized by the animal. In the first 
positivity the white circle indicates the presence of neuroblastoma localized adjacent to the spinal uptake. The 
spinal uptake is present also in the negative scan (thick arrow). Second and third positivity show theevolution of 
tumor; in third positivity the tumoral area presents a dishomogeneous uptake this fact is due to different 
metabolism of cancer cells as a consequence of vascularisation. Sagittal (sagittal section); Coronal (coronal 














Figure 24. MicroPET analysis of tumor progression on an homozyg us mouse in sagital section. This animal 
survived until the fifth positivity. The color scale on the left of each image is the index of the presence of 
radiotracer and it is directly proportional to the concentration of glucose in the tissues of the animl, Yellow 
areas show organ with high metabolic activity, like th  heart, and the site of collection of the drug metabolized 
by the animal, the bladder. The white circle indicates the presence of neuroblastoma localized adjacent to the 





TBR (Tumor-to-Background-Ratio) was calculated for each positive scan of each animal. The 
background uptake is the uptake of a healthy part of the skin because this type of murine 
model develops metastasis in several organs [Weiss]. All tumors diagnosed with microPET 
















Fig. 25. Mean TBR from 25 homozygous mice for each positivity. Mean TBR values correlate with progression 
of the tumoral mass. Each point corresponds to a microPET positivity and it was calculated as the mean from 25 
scans on different animals. The graph shows the exponential increase of the tumor mass during the first three 
microPET positivity and it shows a slight decline in the fourth positivity, probably this is due to the strong 
presence of necrotic tissue in the tumor in the last stage. 
After this analysis, we decided to normalize the uptake index to the real volume of the tumor. 
We did not have the possibility to analyze the tumor with a TAQ scan and for estimate the 
tumor size, thirty five homozygous mice were analyzed with 18F-FDG radiotracer and then 
they were sacrificed to confirm the presence of the tumor and to calculate the tumor volume. 
We divided the progression in five positive points and for each point 7 animals were 








Fig. 26: Mean volume from 7 homozygous mice for each positivity. Each point corresponds to mean value 
obtained from seven tumor samples collected at the same microPET positivity. First positivity corresponds at 3.8 




















After the calculation of mean tumor volume, mean SUV (Standardized Uptake Value) was 
calculated. This semi-quantitative parameter was corre ted with the mean tumor volume of 
each positive point and it showed the increase in tumor malignancy with a negative flexion at 











Fig. 27. Progression of the tumoral mass accorded to SUV values. 
 
3.1.3 Transgenic tumor characterization 
      The autopsy allowed collection tumor samples useful for the histological and molecular 
evaluation. From the post-mortem examination, all positive animals to the evaluation by 
micro-PET have a tumor mass located predominantly in the abdominal region. In the 
advanced stage of tumor progression, the tumor mass alters the structure of the surrounding 
organs, for example it is possible find adhesion part. Both homozygous and hemizygous mice 
tumors don’t present clear difference. The hemizygous tumor is bigger in size respect to 
homozygous tumor. The tumor masses occur heterogeneus in the samples in which it's 
possible to distinguish necrotic regions. It has not yet been found the presence of metastases. 
The tumor presence was confirmed with histological analysis and the presence of human 
MYCN cDNA was seen with immunohistochemistry, molecular and proteomic analysis. 
Histological data confirm that all samples were neuroblastoma. From the analysis of the 









Micro-PET analysis we observed clear difference betwe n the earlier and the last stage of 
develop. In the earliest stage of tumor development it was detected the presence of a small 
tumor mass that sometimes it originated from adrenal gland and we did not see blood vessel. 
In the last stage of development, the tumor mass showed a maturity and progression of the 
angiogenic processes, it was not possible to observe the adrenal gland. In all stage the kidney 




Fig 28. Samples from TH-MYCN mice at different stage of progression form autoptic exam (a-d), H&E staining 
(e-h) and immunohistochemistry with monoclonal anti-MYCN Antibody (j-l). Positive cells are evident in 
brown. 
 
As evident in the Fig.28 on an immunohistochemical assay with the monoclonal 
antibody N-MYC on tumor tissue of homozygous transgenic mice, the majority of cells in the 
samples resulted positive for the presence of N-Myc to the detection with the chromogenic 




















MYCN gene amplification was evaluated in the tumor masses of hemizygous and 
homozygous mice. In both homozygous and hemizygous tumors the MYCN gene 
amplification level was greater than the average gene dosage reported at the time of the 
genotyping. The levels of MYCN oncogene expression in both models were estimated by 
Real Time PCR on reverse transcribed. The expression of MYCN in each model is quite high 
(Fig. 29).  
 




3.2 MYCN-amplified neuroblastoma xenograft 
orthotopic mice models 
       3.2.1 In vitro validation of bioluminescent signal  
      Stably transfected p53wt (Kelly, IMR-32, IMR-5) or p53mut (BE2(c)) MA-NB cells 
subsequently used for in vivo experiments were analyzed to identify the specific luciferase 
emission peak (attended on 560 nm) and to identify a correlation between luciferase 









The results showed that all the cell lines presented a relative luciferase emission peak (560 
nm) (Fig. 30A) highlighting a perfect linear correlation between number of cells used and 












Fig. 30 Quantification oh Photons emitted related to number of cell line (A); overlay of cell signals (B); in vitro 
evaluation of luciferase emission peak (C). 
 
3.2.2 Ex vivo analysis of xenograft orthotopic tumor  
The analysis was performed ex vivo on the tumoral mass removed from specimen at the 





Fig. 31. Tumoral mass of a mouse inoculated with line IMR5-Luc1. F = liver; rs = healthy kidney, kidney involved  





















Figure shows important changes in the distribution of healthy organs because of the high 
dimensions of the mass. The adrenal gland inoculated is indistinguishable from the tumor and 
the kidney below is clearly incorporated by the tumoral tissue but not infiltrated at an initial 
macroscopic examination (arrow), adhesions are also present in liver tissue. The luminescence 
signal ex vivo is much sharper, the layers of skin that in fact define an attenuation of the 
intensity distribution and of the photons detected. This analysis has allowed an assessment of 
the organ specific tumoral mass, the data shown in Figure 38 highlight that there are a lack of 
infiltration in the liver and kidney.  
 
    3.2.3 In vivo bioluminescent imaging  
 
We have generated four new BLI MA-NB xenograft orthtopic murine models, three of 
them carrying p53wt (Kelly, IMR-32 and IMR-5), while one is the first reported carrying 
p53mut (BE2(c)).  All the four tumor mouse models presented a 100% of tumor incidence. 
The MA-NB xenograft orthotopic model harboring p53 mutations (SK-N-BE(2)c) showed a 
tumor characterized by a shorter latency (two weeks) and a higher BLI signal respect the 
p53wt MA-NB xenograft orthotopic mouse models obtained after Kelly and IMR-32 cells 
inoculum (Fig. 32). The IMR-5 model, obtained from a sub clone cell line of IMR-32, showed 








Fig.32 In vivo monitoring of three different NB Xenograft Orthotopic mice models. Graphic rappresentation of 
tumor burden onset and progression at different timepoints (left side); signal detected from Berthold luminograph 














Fig. 33 In vivo monitoring of two different NB Xenograft Orthotopic mice models: the model obtained from the 
original cell line and the model obtained with a sub clone of the same cell line. Graphic rappresentation of tumor 
burden onset and progression at different timepoints (left side); signal detected from Berthold luminograph once 
a week starting one week after day of cells injection (right side). 
 
   3.2.4 Molecular and histological orthotopic tumor        
characterization  
 
All animals were sacrificed after first illness symptoms, and showed abdominal tumor 
mass. The adrenal gland where tumor cells have beeninj cted was not visible and, in some 
cases, the tumor included the other adrenal gland.  
 
Fig.34 H&E staining of Orthotopic MA-NB models confirms the presence of small ruond blue cells. Sample at 
endpoint for IMR-5 (a), BE2(c) (b), IMR-32 (c), and Kelly (d) cell lines. FISH analysis confirms the presence of 










Histopathology analysis highlights the presence of the characteristic “small round blue cells” 
in every p53wt or p53mut MA-NB sample (Fig. 34 a-d). 
 
 The presence of MYCN amplification and overexpression was confirmed by FISH and real 
time quantitative RT-PCR respectively from all the four p53wt or p53mut MA-NB tumors 
(Fig. 35). The levels of expression of MYCN appear to be on average about four times those 
analyzed on the cell line low-Expressed SJ-N-KP. The datum is further corroborated by 
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    3.3 PNA anti-MYCN treatments 
            3.3.1 Cell lines MYCN characterization 
               It's confirmed that the cell lines ued in this experiment have the amplification of 
MYCN oncogene. 
 
Fig 36. FISH analysis of the amplification of the MYCN gene i  neuroblastoma cell lines (a) IMR-32, (b) IMR-5 
(c) SK-N-BE (2)c and of the amplification (d) Kelly (e) SJ-N-KP; Probe "gene specific"= green signal;  

















       3.3.2 In vitro PNA treatment 
At the beginning it was chosen to test the anti-gene PNA s-NLS on the cell line NHO2A 
for the study of the homozygous model.The cells were treated with PNA anti- gene s-NLS 
(PNA anti-gene wild-type, WT) anti-MYCN and PNA anti-gene (PNA anti-gene mut) 10 
mM, for 24, 48, 72, 96 hours. The duration of treatment was derived from analysis of the 
growth curve previously made as up to 96 hours the cells have grown exponentially. Cells 
treated with PNA anti-gene WT at the light microscopy show altered morphology already 
after 8 and 24 hours after treatment, the effect is accentuated after 48 hours, it is very evident 
at 72 hours and still present after 96 hours (Fig. 38). Compared with the control cell K 
(untreated), they tend to move away from the plate and form clusters, have a globular shape, 
very dark and most of the cells die. To test the specificity and the possible toxicity of the PNA 
anti-gene anti-MYCN PNA was used in anti-gene mut, whose sequence has been altered by 
three point mutations. In terms of morphological appearance of the cells treated with the anti-
gene PNA mut is halfway between the control cells and those treated with the anti-gene PNA 
wt. From observations with light microscopy it reveals that some cells tend to detach from the 
plate, but most grow normally, indicating that the PNA anti-gene WT is specific for the 








Fig.38 Cell growth inhibition by anti-MYCN PNA-NLS in NHO2A murine NB cells:morphological analysis. 
 













It was also evaluated cell proliferation following treatment with PNA anti-gene and PNA anti-







Fig.39 Cell growth inhibition by anti-MYCN PNA-NLS in NHO2A murine NB cells: proliferation assay. 
The inhibition of proliferation by 36% at 48 hours and 61% at 72 hours with the PNA anti-
gene WT, while remaining constant at around 16-19% with the anti-gene PNA mut. The 
performance of cells treated with the PNA anti-gene mut is similar to K, while in cells treated 
with the PNA anti-gene WT growth crashes to 72 hours. 
The production of MYCN transgene transcript was evaluated in NHO2A cells, after treatment 
with PNA anti-gene and PNA anti-gene WT and mut 10 µM for 6, 12, 24 and 48 hours. It was 
built a Real-Time PCR semi-quantitative, normalizing the values on the housekeeping gene β-
actin. PNA anti-gene WT significantly inhibits the transcription of MYCN transgene 12 hours 















The analysis was extend to human NB cell lines. The treatment with anti-gene PNA at 24, 48 
and 72 hours shows that the action of the drug is dependent on the cell line considered. The 
Fig.41 shows such Kelly lines and IMR-32 are more susceptible than lines IMR-5 and SK-N-
BE (2)c above 72 hours. The incomplete inhibition of the remaining two lines is also more 
evident always 3 days after treatment. Lines such as IMR-5 and SK-N-BE (2) c are less 
responsive not only to the peptide-nucleic acids..  
 
Fig.41 Cell growth inhibition by anti-MYCN PNA-NLS in human NB cells: proliferation assay. 
 
       3.3.3 In vivo PNA treatment 
To test the effect of PNAwt tumor in vivo, TH-MYCN homozigous mice were treated 
intraperitoneally with doses of  PNAwt (50 mg / kg) or saline, for 20 days from 35 days after 
birth. Tumor growth was assessed by micro-PET with 18F-FDG tracer. The tumor metabolic 
signal was quantified by the TBR value (Target to Background Ratio).The TBR doesn’t show 
a clear decrease in mice treated with PNAwt but thetreated miceshowed a prolongation of the 



























3.4 In vitro and in vivo chemotherapeutical treatments  
In order to improve the therapeutic effect to such cellular histotypes we wanted to study 
the PNA in combination with chemotherapy protocol COJEC. Here then defined dose-
response curves for five chemotherapy drugs is on the lines that have proved resistant to 
peptidonucleic acids, rather than those found to be sensitive. Chemotherapy is currently 
used in the treatment of neuroblastoma is in fact characterized by high toxicity due to the 
incomplete specificity of these drugs to cancer cells. The use of a molecule that does not 
show toxicity as the PNA in combination with these drugs could then work around this 










Fig 44. Dose-response curves for five chemotherapy drugs in four neuroblastoma cell lines with 
amplification of MYCN. CDDP = cisplatin, CBDCA = carboplatin; CPA = cyclophosphamide, VCR = 










Once you have these mouse models of orthotopic nuroblastoma, it was possible to test 
in vivo effect of chemotherapeutic pi `u used in the clinic, particularly vincristine and 
etoposide. 
Therefore, it is chosen to treat orthotopic xenograft model as a model Kelly Luc p53 as wild-
type and mutated p53 is orthotopic xenograft model was used SKNBE (2) c 
Luc. It is decided to use the model inoculated with Kelly instead of the wild-type p53 model 
inoculated with the line IMR-32 Luc is because it has a latency period of five weeks 
3 weeks compared to the model line inoculated with Luc Kelly.  
For this study are used as the drug vincristine andEtoposide. The choice of these 
drugs is established by in vitro laboratory data by focusing on the use of inhibitors 
the spindle and the topoisomerase to the detriment of alkylating agents such as cisplatin and 
carboplatin. 
This pilot study involving 8 murine specimens of 7 weeks, 4 Model 
Kelly SKNBE and 4 for model (2) c. Both models were treated at the beginning of the seventh 
weeks post-inoculation to try to simulate it 'or that happens in the clinic where the 
neuroblastoma 
Agnostic is the market later tively. It should be re corded that they nee Kell y Luc and Luc 
The IMR-32 are derived from a patient at the fourth stage of disease, while the line SKNBE 
(2) c Luc comes one patient relapsed after chemotherapy.The models were monitored by 
"Imaging bioluminescent" by luminometer LB981 Berthold Nightowl to detect the presence 
of tumor initiation, during and end of treatment. 
Underwent chemotherapy 4 xenograft models. The samples were treated with vincristine (0.06 
mg/Kg concentration) for 2 times a week in combinationwith Etoposide (concentration 
14mg/Kg) every 7 days. Both are chemotherapy were administered intraperitoneally for 4 
weeks total.  
The drugs were diluted in saline. For each model were used with 2 controls inoculated 
Kelly and Luc SKNBE line (2) c respectively Luc and treated with saline 3 times 
week for 4 weeks total. The graph in Figure 45 represents the line of survival of orthotopic 
specimens xengraft Kelly Luc undergoing chemotherapy with vincristine and etoposide in 
4 weeks (from 45  to 73  days post-inoculation). Is evident from the graph that the specimens 
undergoing chemotherapy treatment have a higher survival curve 









the development of orthotopic model Kelly. 
 
Fig 45: Survival curve  of Xenograft orthotopic Kelly Luc model 
 
The specimens tested in the study were sacrificed at the first sign of distress. Controls 
receiving saline were sacrificed at 72 and 77 days po t-inoculation while the treated 
with chemotherapy drugs were sacrificed at 90 and 103 days post-inoculation. Samples 
Control survive an average of 74.5 days while the samples treated with chemotherapy 
survive 96.5 days. From this pilot study data show that specimens treated survive 
for 20 days pi `u` compared with controls and can be regarded as a meaningful or 
compared to the average life of a murine model. 
Fig 46 represents the survival curve of the orthotopic xenograft model 
SKNBE (2) C and treated with chemotherapy with vincristine and etoposide. Treatment 
'and ran for four weeks from 45 to 73 days after inoculation days post-inoculation. 
The specimens are subjected to the study sati killed during the treatment period because it is 
showed signs of suffering. While the controls receiving saline were sacrificed 
days to 45 days and 50respectively, were treated with chemotherapy drugs 
sacrificed both at 59 days. The average survival is 47.5 for controls and 59 
models treated with chemotherapy. 
Comparing the survival curve of the two mouse models one may observe that 
inoculated with cells SKNBE (2) c Luc show more aggression `a, as already confirmed in 












Fig 45: Survival curve  of Xenograft orthotopic SKNBE2c Luc model 
 
The models were monitored during treatment and after treatment by 
Nightowl Berthold LB981 luminometer to detect any decrease in the signal 
in the treated specimens compared with controls. 
For this pilot study is not detected a significant reduction of signal in specimens 
treated with chemotherapy compared with controls treated with saline, in both 
models (Kelly and Luc SKNBE (2) c Luc). 
Also according to the statistical analysis with Log rank test (Mantel-Cox), we obtained a value 
P-value of 0.08. The P-value obtained is> 0.05, then the value of survival is not 
significant due to a small number of animals used. 
 
3.5 Toxicological study 
       3.5.1 General toxicological study  
 
To assess the potential toxic effect of PNAwt, histological analysis was performed in all 
major organs, in mice treated with placebo or PNAwt. The analysis showed no significant 
pathological changes in tissues of treated mice compared to those of control mice (Figure 46), 


























Fig 46: Toxicology study. 
 
 
3.5.2 Creation mutant MYCN mice 
Use quantitative genomic PCR to monitor enrichment for he mutant during subcloning. 
To detect a single base mismatch add an additional mismatch on the penultimate base for both 
wild type and mutant targets. During subcloning, the wild type-to-mutant ratio of the seeded 
pools is monitored using qPCR to select the strongest pool and assist in deciding thye density 
at which the next pool is seeded. 















Neuroblastoma remains today the most common and dealy pediatric solid tumor. 
About 25% of Neuroblastoma cases present amplification of MYCN oncogene, which is 
associated with therapy resistance and frequent relaps , with long term survival probabilities 
less than 15%.  
Moreover, high grade of tumor resistance in relapsed cases is often characterized by both 
MYCN-amplification and multitherapy-related p53 gene mutations. Considering this last 
particular aggressive clinical entity, even if accurate preclinical murine models that 
recapitulate MA-NB p53mut are highly needed, they are not described until now. 
MYCN proto-oncogene plays a fundamental role. Its activity contribute to the 









metastasis, resistance to chemotherapy. 
Recent studies highlight how MYCN amplification can regulate the expression of a specific 
pattern of genes leading to a more aggressive phenotype (Westermann F., 2008). In particular 
molecular studies on relapsed Neuroblastoma point out he N-MYC activation of other genes 
responsible of molecular therapies resistance (Keshelava N., 2007; Fontana L., 2008; Pajic 
M., 2005). Although surgery, chemotherapy and radiotherapy are still today capable to 
guarantee an extension of the half-life of patients, the biggest obstacle lies in the 
powerlessness to obtain a complete remission. The low therapeutic efficacy obtained until 
today is caused to a non complete use of the molecular mechanism already emerged that are at 
the base both of the pathology and of a high chemotherapic resistance. 
In our previous studies at the Laboratory of Pediatric Oncology of the University of Bologna, 
we characterized the anti-tumor activity in MYCN-amplified NB cells of a specific anti-
MYCN PNA inhibiting the human MYCN gene expression (Tonelli R. et al, 2005), 
demonstrating a potent and specific anti-tumor activity and apoptosis. The MYCN silencing 
also reduced the MDM2 protein level, rescuing p53 leve s and inducing apoptosis in MNA-
NB cells (Slack A. et al, 2005). In a preliminary previous study, PNA anti-MYCN gene did 
not show toxicity in no-expressing MYCN cells (Tonelli R. et al, 2005). 
The first part of the project has been dedicated to the set up of appropriate preclinical in vitro 
and in vivo model to evaluate the potential therapeutic role of the targeting of MYCN in 
neuroblastoma. 
In particular, we characterized for the first time, the real time tumorigenic evolution of the 
TH-MYCN transgenic homozygous neuroblastoma mouse model, by using Small-animal 
Positron Emission Tomography (PET). This transgenic mouse model in which the expr ssion 
of MYCN is targeted to neural crest cells using the rat tyrosine hydroxylase promoter, closely 
recapitulates human neuroblastoma for molecular, biologic and cytogenetic features, and is an 
optimal immunocompetent model to evaluate new therapi s (TH-MYCN-Weiss, EMBO 1997, 
Chesler, Cancer Res, 2007). 
In this model, we tested for the first time, the accuracy of 18F-fluorodeoxyglucose (18F-FDG) 









the tumor progression in mice transgenic for TH-MYCN.  
The results showed that 18F-FDG was more sensitive that 18F-DOPA for early detection and 
for serial evaluation of malignant progression. Furthe more, the urinary excretion of 18F-
DOPA was very high and urinary bladder radioactivity saturated the images, reducing the 
diagnostic power of the technique.  
Small-animal PET with 18F-FDG in TH-MYCN mice permitted the identification of 
neuroblastoma at an early stage, and offers a sensitive method to follow metabolic progression 
of these tumors. Thus, these results could have potntial indication not only for the tumor 
monitoring in this mouse model, but also have some potential implications in a clinical 
diagnostic view. MicroPET with 18F-FDG was able to visualize the presence of tumor in early 
stage approximately five weeks from birth. 
The use of molecular imaging by small-animal PET in the TH-MYCN mouse model can be 
used to improve the accuracy of in vivo preclinical testing of new therapies for neuroblastoma, 
by ensuring that homogeneous conditions are applied in all the animals under study. 
Moreover, we created three new bioluminescent xenograft orthotopic MA-NB mouse models. 
Two of them carried p53wt, and consistently enrich the only MA-NB p53wt bioluminescent 
mouse model reported until now [28]. 
Moreover, we have reported for the first time a BLI xenograft orthotopic murine model 
carring MA-NB and multitherapy-related p53 mutations i  which this unique allelic variant 
presents a missense mutation that affects its role as guardian of the genome. 
The BLI xenograft orthotopic mice models generated from implanted human MA-NB cell 
lines, characterized by normal or mutated p53, clearly showed tumorigenesis with different 
p53-related progression trends when implanted orthotopically in SCID mice (Fig. 2).  
The mouse model generated from implanted human p53mut MA-NB cells (BE2(c) cells 
deriving from stage 4 p53mut MA-NB after chemotherapic treatment) showed a more 
aggressive tumor evolution that consistently differed from those observed in the other two 









Human neuroblastoma is characterized by a normal p53 status in the majority of the cases at 
the onset [34]. Unfortunately mutations of p53 relat d to chemotherapy and radiotherapy 
treatments often occur [34]. 
The therapy-related mutations in p53 found in NB are generally mutations of a single 
nucleotide resulting in variation of p53 DNA binding domain and therefore affecting its 
normal functions [34]. Tumors harboring these acquired p53 alterations become therefore 
highly resistant to treatment. 
In some cases, according to the 2 hit model proposed by knudson, mutation of one allele is 
followed by the loss of the second one [33]. This hypotesis seems fit exactly with the p53mut 
MA-NB BE2(c) cell line in which only a p53 allelic variant harboring a missense mutation in 
the codon 135 [33].  
The needs to study a possible cytotoxic compound acting in a p53mut independent way 
creates the basis for the creation of preclinical models useful for this kind of studies. 
The transgenic p53wt and p53-haploinsufficient TH-MYCN MA-NB murine model together 
with the bioluminescent orthotopic p53wt MA-NB [19, 28] represent preclinical models in 
which the p53 gene is not mutated but, only in the case of the haploinsufficient model, altered 
in the number of allelic variants. 
The BLI orthotopic xenograft models generated in ths work represent therefore two essential 
and still challenging clinical subset of Neuroblastoma patients: the p53wt MA-NB tumors at 
diagnosis before any chemotherapic treatment (IMR-32 and Kelly) but, more relevant, the 
resistant p53mut MA-NB obtained from a stage 4 patient after classic chemotherapic 
treatment (BE2(c)).  
These models offer the possibility to understand what are the molecular events at the basis of 
different MA-NB tumor progressions allowing targeted preclinical studies in a totally human 
derived tumor in which specific drugs in specific preclinical phases could be tested.  
The p53mut MA-NB BLI xenograft ortothopic model, in particular, offers the possibility to 
test whether or not therapies acting in a p53 independent way could be effective against 









dependent therapy defining a strong chemoresistance.  
Moreover, the ability to follow human tumors growing in vivo represent a model that should 
result more predictive of the behavior of human disease. 
In the second part of the project, the preclinical n vitro and in vivo models has been used to 
evaluate the potential therapeutic role of the targetin  of MYCN in neuroblastoma. 
In vitro studies performed in neuroblastoma cel lines carring MYCN amplification confirmed 
the  Remarkably, the silencing of MYCN by anti-MYCN PNA showed cell growth inibition 
activity also in the multidrug-resistant SK-N-BE cell line, carrying MYCN amplification.  
This result is particularly relevant because showed the potentiality of the pharmacological 
efficacy of a p53-independent MYCN-based therapy. 
Finally we evaluated for the first time, the in vivo anti-tumor activity of an antigene PNA-
MYCN in the TH-MYCN murine model of Neuroblastoma by real-time molecular imaging 
using microPET (36) 
Very remarkably, the treatment of mice with PNA-MYCN led to the tumor metabolic signal in 
the TH-MYCN mice, and significantly prolonged their survival. These in vivo results were 
obtained without the need for continuous treatment, but systemic administration 
(intraperitoneal (IP), 50 mg/kg) every two days for 20 days. Toxicological analysis of PNA-
MYCN in immunocompetent mice after the same treatment schedule did not reveal any signs 
of toxicity.  
 
Overall, our results indicate that the targeting of N-Myc has potential critical therapeutic role 
in MYCN-amplified Neuroblastoma and supports development of systemic oligonucleotide 
anti-MYCN-gene therapy for the treatment of Neuroblstoma, the most deadly and devastating 
form of childhood cancer. We have demonstrated potential clinical suitability of an antigene 
strategy through its cellular and molecular activity, ability to specifically inhibit transcription 
and in vivo efficacy with no evidence for toxicity.  
In the present study regarding the in vitro studies, the construction of dose-response curves 









It has enabled not only to classify the drugs according to their effectiveness 
`ı but also to distinguish the different cell lines according to their sensibility to the following 
used drugs: vincristine, Cispolatino, Carboplatin, Etoposide. Among the four compounds 
the one with the most cytotoxic effect is Vincristine. This efficiency could be 
`ad'azione due to the high specificity of the drug vincristine is in fact an inhibitor of cell 
specific cycle. It causes cell death only when target M 
not allowing the cell cycle, unlike other drugs, the trigger mechanisms 
shelter. The cell stops at M until the microtubules connecting the kinetochore, where 
this does not happen to be in the cell apoptosis. 
This in vitro study attempts to reflect the treatment being used in the clinic according to the 
protocol 
European COJEC NB-AR-01. In addition to drugs used in our study provides the COJEC 
the use of cyclophosphamide. To date it has not been possible to use this medication Because 
in bioactivation needs a liver to become ciclofosfoamide 4-hydroxy (4-OH CP) 
to complete its cytotoxic effects of mustard Phosphoramides [151] through the enzymes 
P450. 
in this regard, to test the models and their respone to drugs, in this study is 
The effect of anticancer drugs in one of two models of wild-type p53 neuroblastoma, 
Kelly Luc, and the model with mutated p53, SKNBE (2) c Luc. 
Although only a preliminary pilot study on a small court of specimens, is significantly 
given the survival of both models treated. The results 
confirmed in vitro and clinical data and validate the increased aggressiveness of the tumor-
derived `a 
SKNBE line (2) c neuroblastoma tumor in relapsed stage 4. The results reveal 
that the specimens p53 wild-type treated with chemotherapy have an extension of 
survival of 25 days compared to the life of an animal is a mouse given 
significant. 
However, this study as a "pilot"needs more data to c nfirm the result 
obtained. 
Even if MMR raises a strong barrier to succeful olig nucleotide mediated gene targeting 
in ES cell, the transient down regulation of MMR activity thanks to transient suppression of 
MLH1 by RNA interference [174]. I have succesfully applied the oligotargeting method to 









to generate the first mutant mouse line that was created via single base oligonucleotide-
mediated gene targeting. Generation of mutant mice by 1 nt modification in ES cell, which are 
germ line competent.The basal mechanism of ssODN-mediated gene targeting is not yet fully 
understood but the proposed model sees ssODN annealing to its chromosomal complement 
within the context of a replication fork. The single stranded DNA regions present during DNA 
synthesis may enhance ssODN annealing. This best accessibility may explain why also in my 
experiment ssODNs in the sense orientation performed better than ssODNs in the anti-sense 
orientation. I have successfully applied this strategy to generate the first mutant mouse that 
presents a single base mutation in its genome.  Oligonucleotide-modified MYCN allele can be 
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